{"protocolSection":{"identificationModule":{"nctId":"NCT03631199","orgStudyIdInfo":{"id":"CACZ885U2301"},"secondaryIdInfos":[{"id":"2024-511490-29-00","type":"REGISTRY","domain":"EU CT Number"}],"organization":{"fullName":"Novartis","class":"INDUSTRY"},"briefTitle":"Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)","acronym":"CANOPY-1"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-12-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-08-09","type":"ACTUAL"},"completionDateStruct":{"date":"2027-06-07","type":"ESTIMATED"},"studyFirstSubmitDate":"2018-08-06","studyFirstSubmitQcDate":"2018-08-10","studyFirstPostDateStruct":{"date":"2018-08-15","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-07-05","resultsFirstSubmitQcDate":"2024-09-27","resultsFirstPostDateStruct":{"date":"2024-10-08","type":"ACTUAL"},"dispFirstSubmitDate":"2022-07-11","dispFirstPostDateStruct":{"date":"2024-10-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-19","lastUpdatePostDateStruct":{"date":"2025-09-22","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novartis Pharmaceuticals","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This was a Phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC participants.","detailedDescription":"The study primarily assessed the safety and tolerability (safety run-in Part A) of pembrolizumab plus platinum-based doublet chemotherapy with canakinumab, and then, the efficacy (double-blind, randomized, placebo-controlled Part B) of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"],"keywords":["ACZ885","canakinumab","pembrolizumab","carboplatin","cisplatin","paclitaxel","nab-paclitaxel","pemetrexed","NSCLC","non-small cell lung cancer","non small cell lung cancer","squamous","non-squamous","hsCRP","IL-1β","PD-L1","CANOPY","CANOPY-1","platinum-based doublet chemotherapy","first line therapy","locally advanced","metastatic"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":673,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Part 1: Cohort A","type":"EXPERIMENTAL","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and pemetrexed.","interventionNames":["Drug: canakinumab","Drug: pembrolizumab","Drug: carboplatin","Drug: pemetrexed"]},{"label":"Part 1: Cohort B","type":"EXPERIMENTAL","description":"Safety run-in, canakinumab in combination with pembrolizumab, cisplatin, and pemetrexed.","interventionNames":["Drug: canakinumab","Drug: pembrolizumab","Drug: cisplatin","Drug: pemetrexed"]},{"label":"Part 1: Cohort C","type":"EXPERIMENTAL","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and paclitaxel.","interventionNames":["Drug: canakinumab","Drug: pembrolizumab","Drug: carboplatin","Drug: paclitaxel"]},{"label":"Part 2: Canakinumab+pembro+CTx","type":"EXPERIMENTAL","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy.","interventionNames":["Drug: canakinumab","Drug: pembrolizumab","Drug: carboplatin","Drug: cisplatin","Drug: paclitaxel","Drug: nab-paclitaxel","Drug: pemetrexed"]},{"label":"Part 2: Placebo+pembro+CTx","type":"OTHER","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy.","interventionNames":["Drug: canakinumab-matching placebo","Drug: pembrolizumab","Drug: carboplatin","Drug: cisplatin","Drug: paclitaxel","Drug: nab-paclitaxel","Drug: pemetrexed"]}],"interventions":[{"type":"DRUG","name":"canakinumab","description":"canakinumab 200 mg subcutaneous (s.c.) injection every 3 weeks (squamous and non-squamous)","armGroupLabels":["Part 1: Cohort A","Part 1: Cohort B","Part 1: Cohort C","Part 2: Canakinumab+pembro+CTx"],"otherNames":["ACZ885"]},{"type":"DRUG","name":"canakinumab-matching placebo","description":"canakinumab placebo every 3 weeks (squamous and non-squamous)","armGroupLabels":["Part 2: Placebo+pembro+CTx"]},{"type":"DRUG","name":"pembrolizumab","description":"200 mg every 3 weeks (squamous and non-squamous)","armGroupLabels":["Part 1: Cohort A","Part 1: Cohort B","Part 1: Cohort C","Part 2: Canakinumab+pembro+CTx","Part 2: Placebo+pembro+CTx"]},{"type":"DRUG","name":"carboplatin","description":"Area Under the Curve (AUC) 5 mg/mL\\*min every 3 weeks (non-squamous) or AUC 6 mg/mL\\*min (squamous)","armGroupLabels":["Part 1: Cohort A","Part 1: Cohort C","Part 2: Canakinumab+pembro+CTx","Part 2: Placebo+pembro+CTx"]},{"type":"DRUG","name":"cisplatin","description":"75 mg/m\\^2 every 3 weeks (non-squamous)","armGroupLabels":["Part 1: Cohort B","Part 2: Canakinumab+pembro+CTx","Part 2: Placebo+pembro+CTx"]},{"type":"DRUG","name":"paclitaxel","description":"200 mg/m\\^2 every 3 weeks (squamous)","armGroupLabels":["Part 1: Cohort C","Part 2: Canakinumab+pembro+CTx","Part 2: Placebo+pembro+CTx"]},{"type":"DRUG","name":"nab-paclitaxel","description":"100 mg/m\\^2 on Days 1, 8, and 15 of every cycle (squamous)","armGroupLabels":["Part 2: Canakinumab+pembro+CTx","Part 2: Placebo+pembro+CTx"]},{"type":"DRUG","name":"pemetrexed","description":"500 mg/m\\^2 every 3 weeks (non-squamous)","armGroupLabels":["Part 1: Cohort A","Part 1: Cohort B","Part 2: Canakinumab+pembro+CTx","Part 2: Placebo+pembro+CTx"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part 1 (Safety Run-in): Number of Participants With Dose-limiting Toxicities (DLTs)","description":"A DLT was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease progression, inter-current illness, or concomitant medications that met certain criteria as defined in the protocol.","timeFrame":"During the first 42 days of dosing"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Progression-free Survival (PFS) Per Investigator Assessment Using RECIST v1.1","description":"Progression free survival was defined as the time from randomization to the date of the first documented radiological progression using RECIST 1.1 (Response evaluation criteria in solid tumor) or death due to any cause.","timeFrame":"18 months"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Overall Survival (OS) Per Investigator Assessment Using RECIST v1.1","description":"Overall survival is defined as the time from date of randomization to date of death due to any cause.","timeFrame":"Up to approximately 32 months"}],"secondaryOutcomes":[{"measure":"Part 1 (Safety Run-in): Overall Response Rate (ORR) Per Investigator Assessment Using RECIST v1.1","description":"ORR was defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","timeFrame":"Up to approximately 14 months"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Overall Response Rate (ORR) Per Investigator Assessment Using RECIST v1.1","description":"ORR was defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","timeFrame":"Up to approximately 26 months"},{"measure":"Part 1 (Safety run-in): Disease Control Rate (DCR) Per Investigator Assessment Using RECIST v1.1","description":"Disease control rate was defined as the percentage of participants with complete response (CR) or partial response (PR) or participants with stable disease (SD) as per investigator assessment according to RECIST 1.1 criteria. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters; SD=Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.","timeFrame":"Up to approximately 14 months"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Disease Control Rate (DCR) Per Investigator Assessment Using RECIST v1.1","description":"Disease control rate was defined as the percentage of participants with complete response (CR) or partial response (PR) or participants with stable disease (SD) as per investigator assessment according to RECIST 1.1 criteria. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters; SD=Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.","timeFrame":"Up to approximately 26 months"},{"measure":"Part 1 (Safety run-in): Duration of Response (DOR) Per Investigator Assessment Using RECIST v1.1","description":"Duration of response was defined as the time from first documented response of CR or PR to date of first documented progression or death due to any cause, according to RECIST 1.1 criteria. DOR only applied to participants whose best overall response was CR or PR based on tumor response data per local review. If a participant did not have an event, DOR was censored at the date of last adequate tumor assessment. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","timeFrame":"Up to approximately 25 months"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Duration of Response (DOR) Per Investigator Assessment Using RECIST v1.1","description":"Duration of response was defined as the time from first documented response of CR or PR to date of first documented progression or death due to any cause, according to RECIST 1.1 criteria. DOR only applied to participants whose best overall response was CR or PR based on tumor response data per local review. If a participant did not have an event, DOR was censored at the date of last adequate tumor assessment. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","timeFrame":"Up to approximately 26 months"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Time to Response (TTR) Per Investigator Assessment Using RECIST v1.1","description":"Time to response (TTR) was defined as duration of time between the date of randomization and the date of first documented response of either CR or PR, according to RECIST 1.1 criteria. Duration of response was defined as the time from first documented response of CR or PR to date of first documented progression or death due to any cause, according to RECIST 1.1 criteria. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","timeFrame":"Up to approximately 26 months"},{"measure":"Part 1 (Safety Run-in): Antidrug Antibodies (ADA) of Canakinumab","description":"Participants with at least one ADA-positive sample.","timeFrame":"Predose (0 hours (h)) on Day 1 of Cycles 1, 4, 8, 12, 16 (Cycle length =21 days), at end of treatment & then at 26, 78 and 130 days after last dose"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Number of Participants With Antidrug Antibodies (ADA) of Canakinumab","description":"Participants with at least one ADA-positive sample.","timeFrame":"Up to approximately 26 months"},{"measure":"Part 1 (Safety run-in): Antidrug Antibodies (ADAs) of Pembrolizumab","description":"Participants with at least one ADA-positive sample.","timeFrame":"Predose (0 h) on Day 1 of Cycles 1, 2, 4, 8, 12, 16 (Cycle length =21 days), at end of treatment & then at 26 days after last dose"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Antidrug Antibodies (ADA) of Pembrolizumab","description":"Participants with at least one ADA-positive sample.","timeFrame":"Up to approximately 26 months"},{"measure":"Part 1 (Safety Run-in): Serum Canakinumab Concentration","timeFrame":"Predose (0 h) on Day 1 of Cycles 1-6, 8, 12, 16, Postdose on day 2, 8, 15 of Cycle 1, Post dose on Cycle 5 day 8, at end of treatment & then at 26, 78 and 130 days after last dose (Cycle length =21 days)"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Serum Canakinumab Concentration","timeFrame":"Predose (0 h) on Day 1 of Cycles 1-6, 8, 12, 16, Postdose on day 2, 8, 15 of Cycle 1, Post dose on Cycle 5 day 8, at end of treatment & then at 26, 78 and 130 days after last dose (Cycle length =21 days)"},{"measure":"Part 1 (Safety Run-in): Serum Pembrolizumab Concentration","timeFrame":"Predose (0 h) on Day 1 of Cycles 1-6, 8, 12, 16, Postdose on day 2, 8, 15 of Cycle 1, at end of treatment & then at 26 days after last dose (Cycle length =21 days)"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Serum Pembrolizumab Concentration","timeFrame":"Predose (0 h) on Day 1 of Cycles 1-6, 8, 12, 16, Postdose on day 2, 8, 15 of Cycle 1, at end of treatment & then at 26 days after last dose (Cycle length =21 days)"},{"measure":"Part 1 (Safety Run-in): Plasma Pemetrexed Concentration","timeFrame":"Predose (0 h) and end of infusion on Cycle 1 and 2; 1, 4, 8 h post infusion on Cycle 1; 1, 2, 4, 8h post infusion on Cycle 2 (Cycle length =21 days)"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Pemetrexed Concentration","timeFrame":"Predose (0 h) and end of infusion on Cycle 1 and 2; 1, 4, 8 h post infusion on Cycle 1; 1, 2, 4, 8h post infusion on Cycle 2 (Cycle length =21 days)"},{"measure":"Part 1 (Safety Run-in): Plasma Cisplatin Concentration","timeFrame":"Predose (0 h) and end of infusion on Cycle 1 and 2; 2, 4, 8 h post infusion on Cycle 1; 1.5, 2, 4, 8 h post infusion on Cycle 2 (Cycle length =21 days)"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Cisplatin Concentration","timeFrame":"Predose (0 h) and end of infusion on Cycle 1 and 2; 2, 4, 8 h post infusion on Cycle 1; 1.5, 2, 4, 8 h post infusion on Cycle 2 (Cycle length = 21 days)"},{"measure":"Part 1 (Safety Run-in): Plasma Carboplatin Concentration","timeFrame":"Predose (0 h), end of infusion, 1, 2, 4, 8 h post infusion on Cycles 1 and 2 (Cycle length =21 days)"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Carboplatin Concentration","timeFrame":"Predose (0 h), end of infusion, 1, 2, 4, 8 h post infusion on Cycles 1 and 2 (Cycle length =21 days)"},{"measure":"Part 1 (Safety Run-in): Plasma Paclitaxel Concentration","timeFrame":"Predose (0 h) and end of infusion on Cycle 1 and 2; 4, 8, 12 h post infusion on Cycle 1; 4, 6, 8, 12 h post infusion on Cycle 2 (Cycle length =21 days)"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Paclitaxel Concentration","timeFrame":"Predose (0 h) and end of infusion on Cycle 1 and 2; 4, 8, 12 h post infusion on Cycle 1; 4, 6, 8, 12 h post infusion on Cycle 2 (Cycle length =21 days)"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Nab-paclitaxel Concentration","timeFrame":"Predose (0 h) and end of infusion on Cy 1 and 2, 4, 8, 12 h post infusion on Cy 1, 4, 6, 8, 12 h post infusion on Cy 2 (Cy length =21 days)"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Time to Definitive 10-point Deterioration (TTDD) Symptom Scores of Pain, Cough and Dyspnea Per EORTC QLQ-LC13 Questionnaire","description":"The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) comprises both multi-item and single-item measures of lung cancer-associated symptoms (ie, coughing, dyspnea, and chest pain). Scores for each scale and single-item range from 0 to 100, with higher scores indicating higher level of symptoms. TTDD for chest pain, cough and dyspnea was defined as the time from randomization to the date of event, which was defined as at least 10 points absolute worsening from baseline of the corresponding scale score, with no later change below this threshold ie.\\<10 points was observed, or if this worsening was observed at the last assessment for the subject, or death due to any cause (whichever occurred earlier). If a subject did not have an event, TTDD was censored at the last adequate assessment.","timeFrame":"Up to approximately 25 months"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Time to Definitive Deterioration in Global Health Status/Quality of Life, Shortness of Breath and Pain Per EORTC QLQ-C30 Questionnaire","description":"The European Organization for Research and Treatment of Cancer quality of life (EORTC QLQ-C30) is a questionnaire developed to assess the health-related quality of life of cancer participants. It assesses 15 domains consisting of 5 functional domains (physical, role, emotional, cognitive, social) and 9 symptom domains (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties) and a global health status/QoL scale. All domain scores range from 0 to 100. A high score for the functional or global health status scales indicates a high level of functioning or QoL; a high score for a symptom scale indicates a high level of symptoms.","timeFrame":"Up to approximately 25 months"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Change From Baseline in Score as Per the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Questionnaire","description":"The EQ-5D-5L questionnaire is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L measures 5 items on mobility, self-care, usual activities, pain/discomfort, anxiety/depression, measured on 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. A utility index can be computed from the EQ 5D-5L descriptive system with utility scores ranging from -0.281 (worst imaginable health state) to 1 (best imaginable health state), with -0.281 representing an \"unconscious\" health state. A single index value is analyzed for the EQ-5D-5L score. An increase from baseline in the EQ-ED-5L utility index is indicative of an improvement.). CFB = change from baseline","timeFrame":"Assessed every 3 weeks from Week 3 through Week 108, at follow-up visits 1, 2, 3, 4, and 5 (follow-up visits occurred every 26 days from week 108), and at 7 and 28 days post-disease progression, all up to a maximum of 3.5 years"},{"measure":"Part 2 (Double-blind, Randomized, Placebo-controlled): Change From Baseline in Score as Per the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Questionnaire - Visual Analog Scale (VAS)","description":"The EQ-5D-5L is a standardized questionnaire used to assess health-related quality of life, and it includes a Visual Analog Scale (VAS). The VAS score is obtained by asking the individual to rate their current health status on a scale from 0 to 100, where 0 represents the worst possible health state and 100 represents the best possible health state.\n\nThe change from baseline in EQ-5D-5L VAS score was calculated. A positive change from baseline indicates improvement in the health status. CFB = change from baseline","timeFrame":"Assessed every 3 weeks from Week 3 through Week 108, at follow-up visits 1, 2, 3, 4, and 5 (follow-up visits occurred every 26 days from week 108), and at 7 and 28 days post-disease progression, all up to a maximum of 3.5 years"}]},"eligibilityModule":{"eligibilityCriteria":"Key inclusion criteria:\n\n* Histologically confirmed locally advanced stage IIIB or stage IV NSCLC for treatment in the first-line setting\n* Known PD-L1 status determined by a Novartis designated central laboratory. A newly obtained tissue biopsy or an archival biopsy (block or slides) is required for PD-L1 determination (PD-L1 IHC 22C3 pharmDx assay), prior to study randomization. Note: For the safety run-in part, known PD-L1 status is not required.\n* Eastern Cooperative oncology group (ECOG) performance status of 0 or 1.\n* At least 1 measurable lesion by RECIST 1.1\n\nKey exclusion criteria:\n\n* Previous immunotherapy (e.g. anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways).\n* Prior treatment with canakinumab or drugs of a similar mechanism of action (IL-1β inhibitor).\n* Subjects with epidermal growth factor receptor (EGFR) sensitizing mutations (identified in exons 19, 20, or 21), and/or ALK rearrangement by locally approved laboratory testing.\n* Previously untreated or symptomatic central nervous system (CNS) metastases or lepto-meningeal disease.\n* Subject with suspected or proven immune-compromised state or infections.\n* Subject has prior to starting study drug: received live vaccination ≤3 months, had major surgery ≤4 weeks prior to starting study drug, has thoracic radiotherapy: lung fields ≤ 4 weeks, other anatomic sites ≤ 2 weeks, palliative radiotherapy for bone lesions ≤ 2 weeks.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Novartis Pharmaceuticals","affiliation":"Novartis Pharmaceuticals","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Pacific Shores Medical Group","city":"Long Beach","state":"California","zip":"90813","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"USC Kenneth Norris Comprehensive Cancer Center","city":"Los Angeles","state":"California","zip":"90033","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Advent Health Cancer Institute","city":"Orlando","state":"Florida","zip":"32804","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Dana Farber Cancer Institute","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Novartis Investigative Site","city":"CABA","state":"Buenos Aires","zip":"C1426ANZ","country":"Argentina"},{"facility":"Novartis Investigative Site","city":"Caba","zip":"C1431FWO","country":"Argentina"},{"facility":"Novartis Investigative Site","city":"Westmead","state":"New South Wales","zip":"2145","country":"Australia","geoPoint":{"lat":-33.80383,"lon":150.98768}},{"facility":"Novartis Investigative Site","city":"Wooloongabba","state":"Queensland","zip":"4102","country":"Australia"},{"facility":"Novartis Investigative Site","city":"Melbourne","state":"Victoria","zip":"3000","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Novartis Investigative Site","city":"Murdoch","state":"Western Australia","zip":"6150","country":"Australia","geoPoint":{"lat":-32.06987,"lon":115.83757}},{"facility":"Novartis Investigative Site","city":"Linz","state":"Upper Austria","zip":"A 4020","country":"Austria","geoPoint":{"lat":48.30639,"lon":14.28611}},{"facility":"Novartis Investigative Site","city":"Salzburg","zip":"5020","country":"Austria","geoPoint":{"lat":47.79941,"lon":13.04399}},{"facility":"Novartis Investigative Site","city":"Barretos","state":"São Paulo","zip":"14784 400","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"Novartis Investigative Site","city":"São Paulo","state":"São Paulo","zip":"01246 000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Novartis Investigative Site","city":"São Paulo","state":"São Paulo","zip":"04014-002","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Novartis Investigative Site","city":"Edmonton","state":"Alberta","zip":"T6G 1Z2","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Novartis Investigative Site","city":"Brampton","state":"Ontario","zip":"L6R 3J7","country":"Canada","geoPoint":{"lat":43.68341,"lon":-79.76633}},{"facility":"Novartis Investigative Site","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Novartis Investigative Site","city":"Temuco","state":"Región de la Araucanía","zip":"4810469","country":"Chile","geoPoint":{"lat":-38.73628,"lon":-72.59738}},{"facility":"Novartis Investigative Site","city":"Santiago","zip":"8420383","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Novartis Investigative Site","city":"Harbin","state":"Heilongjiang","zip":"150081","country":"China","geoPoint":{"lat":45.75,"lon":126.65}},{"facility":"Novartis Investigative Site","city":"Wuhan","state":"Hubei","zip":"430022","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Novartis Investigative Site","city":"Wuhan","state":"Hubei","zip":"430030","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Novartis Investigative Site","city":"Changsha","state":"Hunan","zip":"410013","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"Novartis Investigative Site","city":"Changchun","state":"Jilin","zip":"130012","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Novartis Investigative Site","city":"Xi’an","state":"Shanxi","zip":"710038","country":"China","geoPoint":{"lat":35.99785,"lon":113.52486}},{"facility":"Novartis Investigative Site","city":"Hangzhou","state":"Zhejiang","zip":"310022","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Novartis Investigative Site","city":"Beijing","zip":"100036","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Novartis Investigative Site","city":"Valledupar","state":"Cesar Department","zip":"5602310","country":"Colombia","geoPoint":{"lat":10.46538,"lon":-73.2531}},{"facility":"Novartis Investigative Site","city":"Ostrava","state":"Vitkovice","zip":"703 84","country":"Czechia","geoPoint":{"lat":49.83465,"lon":18.28204}},{"facility":"Novartis Investigative Site","city":"Brno","zip":"625 00","country":"Czechia","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Novartis Investigative Site","city":"Brno","zip":"656 53","country":"Czechia","geoPoint":{"lat":49.19522,"lon":16.60796}},{"facility":"Novartis Investigative Site","city":"Prague","zip":"128 08","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Novartis Investigative Site","city":"Herning","zip":"7400","country":"Denmark","geoPoint":{"lat":56.13615,"lon":8.97662}},{"facility":"Novartis Investigative Site","city":"Oulu","zip":"FIN-90220","country":"Finland","geoPoint":{"lat":65.01236,"lon":25.46816}},{"facility":"Novartis Investigative Site","city":"Marseille","state":"Bouches Du Rhone","zip":"13915","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Novartis Investigative Site","city":"Lyon","zip":"69373","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Novartis Investigative Site","city":"Montpellier","zip":"34070","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"Novartis Investigative Site","city":"Nantes","zip":"44093","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Novartis Investigative Site","city":"Paris","zip":"75231","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Novartis Investigative Site","city":"Munich","state":"Bavaria","zip":"81377","country":"Germany","geoPoint":{"lat":48.13743,"lon":11.57549}},{"facility":"Novartis Investigative Site","city":"Göttingen","state":"Lower Saxony","zip":"37075","country":"Germany","geoPoint":{"lat":51.53443,"lon":9.93228}},{"facility":"Novartis Investigative Site","city":"Cologne","state":"North Rhine-Westphalia","zip":"51109","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Novartis Investigative Site","city":"Dresden","state":"Saxony","zip":"01307","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"Novartis Investigative Site","city":"Leipzig","state":"Saxony","zip":"04347","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Novartis Investigative Site","city":"Halle","state":"Saxony-Anhalt","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"Novartis Investigative Site","city":"Berlin","zip":"13125","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Novartis Investigative Site","city":"Cologne","zip":"50937","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Novartis Investigative Site","city":"Essen","zip":"45147","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Novartis Investigative Site","city":"Georgsmarienhütte","zip":"49124","country":"Germany","geoPoint":{"lat":52.20296,"lon":8.0448}},{"facility":"Novartis Investigative Site","city":"Gerlingen","zip":"70839","country":"Germany","geoPoint":{"lat":48.79954,"lon":9.06316}},{"facility":"Novartis Investigative Site","city":"Heidelberg","zip":"69120","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Novartis Investigative Site","city":"Athens","state":"GR","zip":"115 27","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Novartis Investigative Site","city":"Athens","zip":"185 47","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"Novartis Investigative Site","city":"Kowloon","zip":"999999","country":"Hong Kong","geoPoint":{"lat":22.31667,"lon":114.18333}},{"facility":"Novartis Investigative Site","city":"Kowloon","country":"Hong Kong","geoPoint":{"lat":22.31667,"lon":114.18333}},{"facility":"Novartis Investigative Site","city":"Veszprém","zip":"8200","country":"Hungary","geoPoint":{"lat":47.09327,"lon":17.91149}},{"facility":"Novartis Investigative Site","city":"Reykjavik","zip":"IS-101","country":"Iceland","geoPoint":{"lat":64.13548,"lon":-21.89541}},{"facility":"Novartis Investigative Site","city":"Hyderabad","state":"Andhra Pradesh","zip":"500 034","country":"India"},{"facility":"Novartis Investigative Site","city":"Gurgaon","state":"Haryana","zip":"122 001","country":"India","geoPoint":{"lat":28.4601,"lon":77.02635}},{"facility":"Novartis Investigative Site","city":"Pune","state":"Maharashtra","zip":"411013","country":"India","geoPoint":{"lat":18.51957,"lon":73.85535}},{"facility":"Novartis Investigative Site","city":"Jaipur","state":"Rajasthan","zip":"302017","country":"India","geoPoint":{"lat":26.91962,"lon":75.78781}},{"facility":"Novartis Investigative Site","city":"Hyderabad","state":"Telangana","zip":"500082","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"Novartis Investigative Site","city":"Kolkata","state":"West Bengal","zip":"700160","country":"India","geoPoint":{"lat":22.56263,"lon":88.36304}},{"facility":"Novartis Investigative Site","city":"Avellino","state":"AV","zip":"83100","country":"Italy","geoPoint":{"lat":40.91494,"lon":14.79103}},{"facility":"Novartis Investigative Site","city":"Genova","state":"GE","zip":"16132","country":"Italy","geoPoint":{"lat":45.21604,"lon":11.87211}},{"facility":"Novartis Investigative Site","city":"Milan","state":"MI","zip":"20132","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Novartis Investigative Site","city":"Milan","state":"MI","zip":"20133","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Novartis Investigative Site","city":"Milan","state":"MI","zip":"20141","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Novartis Investigative Site","city":"Rozzano","state":"MI","zip":"20089","country":"Italy","geoPoint":{"lat":45.38193,"lon":9.1559}},{"facility":"Novartis Investigative Site","city":"Modena","state":"MO","zip":"41124","country":"Italy","geoPoint":{"lat":44.64783,"lon":10.92539}},{"facility":"Novartis Investigative Site","city":"Padua","state":"PD","zip":"35100","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}},{"facility":"Novartis Investigative Site","city":"Perugia","state":"PG","zip":"06129","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"Novartis Investigative Site","city":"Parma","state":"PR","zip":"43126","country":"Italy","geoPoint":{"lat":44.79935,"lon":10.32618}},{"facility":"Novartis Investigative Site","city":"Orbassano","state":"TO","zip":"10043","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"Novartis Investigative Site","city":"Nagoya","state":"Aichi-ken","zip":"464 8681","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Novartis Investigative Site","city":"Sapporo","state":"Hokkaido","zip":"060 8648","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Novartis Investigative Site","city":"Himeji","state":"Hyōgo","zip":"670-8520","country":"Japan","geoPoint":{"lat":34.81667,"lon":134.7}},{"facility":"Novartis Investigative Site","city":"Yokohama","state":"Kanagawa","zip":"241-8515","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Novartis Investigative Site","city":"Sakai","state":"Osaka","zip":"591-8555","country":"Japan","geoPoint":{"lat":34.58216,"lon":135.46653}},{"facility":"Novartis Investigative Site","city":"Sunto Gun","state":"Shizuoka","zip":"411 8777","country":"Japan"},{"facility":"Novartis Investigative Site","city":"Chuo Ku","state":"Tokyo","zip":"104 0045","country":"Japan"},{"facility":"Novartis Investigative Site","city":"Ube","state":"Yamaguchi","zip":"755-0241","country":"Japan","geoPoint":{"lat":33.94306,"lon":131.25111}},{"facility":"Novartis Investigative Site","city":"Osaka","zip":"545-8586","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Novartis Investigative Site","city":"Beirut","zip":"166830","country":"Lebanon","geoPoint":{"lat":33.89332,"lon":35.50157}},{"facility":"Novartis Investigative Site","city":"Saida","zip":"652","country":"Lebanon","geoPoint":{"lat":33.55751,"lon":35.37148}},{"facility":"Novartis Investigative Site","city":"Kuala Lumpur","state":"Kuala Lumpur","zip":"50586","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"facility":"Novartis Investigative Site","city":"Kuantan","state":"Pahang","zip":"25100","country":"Malaysia","geoPoint":{"lat":3.8077,"lon":103.326}},{"facility":"Novartis Investigative Site","city":"Kuching","state":"Sarawak","zip":"93586","country":"Malaysia","geoPoint":{"lat":1.55,"lon":110.33333}},{"facility":"Novartis Investigative Site","city":"Kuala Lumpur","zip":"59100","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"facility":"Novartis Investigative Site","city":"Groningen","zip":"9713 GZ","country":"Netherlands","geoPoint":{"lat":53.21917,"lon":6.56667}},{"facility":"Novartis Investigative Site","city":"Groningen","zip":"9728 NZ","country":"Netherlands","geoPoint":{"lat":53.21917,"lon":6.56667}},{"facility":"Novartis Investigative Site","city":"Drammen","zip":"3004","country":"Norway","geoPoint":{"lat":59.74389,"lon":10.20449}},{"facility":"Novartis Investigative Site","city":"City of Taguig","state":"National Capital Region","zip":"1634","country":"Philippines","geoPoint":{"lat":14.5243,"lon":121.0792}},{"facility":"Novartis Investigative Site","city":"Makati City","zip":"1229","country":"Philippines","geoPoint":{"lat":14.55027,"lon":121.03269}},{"facility":"Novartis Investigative Site","city":"Quezon","zip":"1102","country":"Philippines","geoPoint":{"lat":7.73028,"lon":125.09889}},{"facility":"Novartis Investigative Site","city":"San Juan City","zip":"1500","country":"Philippines","geoPoint":{"lat":14.6,"lon":121.0333}},{"facility":"Novartis Investigative Site","city":"Gliwice","zip":"44 101","country":"Poland","geoPoint":{"lat":50.29761,"lon":18.67658}},{"facility":"Novartis Investigative Site","city":"Poznan","zip":"60 569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Novartis Investigative Site","city":"Tomaszw Mazowiecki","zip":"97-200","country":"Poland"},{"facility":"Novartis Investigative Site","city":"Lisbon","zip":"1769 001","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Novartis Investigative Site","city":"Porto","zip":"4200-072","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Novartis Investigative Site","city":"Craiova","state":"Dolj","zip":"200347","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Novartis Investigative Site","city":"Cluj-Napoca","zip":"400124","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Novartis Investigative Site","city":"Arkhangelsk","zip":"163045","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"facility":"Novartis Investigative Site","city":"Omsk","zip":"644013","country":"Russia","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"Novartis Investigative Site","city":"Pushkin Saint Petersburg","zip":"196603","country":"Russia"},{"facility":"Novartis Investigative Site","city":"Saint Petersburg","zip":"192148","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Novartis Investigative Site","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Novartis Investigative Site","city":"Singapore","zip":"119228","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Novartis Investigative Site","city":"Singapore","zip":"168583","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Novartis Investigative Site","city":"Singapore","zip":"S308433","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"Novartis Investigative Site","city":"Bratislava","zip":"83310","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"Novartis Investigative Site","city":"Partizánske","zip":"958 01","country":"Slovakia","geoPoint":{"lat":48.62861,"lon":18.38455}},{"facility":"Novartis Investigative Site","city":"Gyeonggi-do","state":"Korea","zip":"10408","country":"South Korea","geoPoint":{"lat":37.58944,"lon":126.76917}},{"facility":"Novartis Investigative Site","city":"Seoul","state":"Seocho Gu","zip":"06591","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Novartis Investigative Site","city":"Seoul","zip":"03080","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Novartis Investigative Site","city":"Seoul","zip":"03722","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Novartis Investigative Site","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Novartis Investigative Site","city":"Granada","state":"Andalusia","zip":"18014","country":"Spain","geoPoint":{"lat":37.18817,"lon":-3.60667}},{"facility":"Novartis Investigative Site","city":"Donostia / San Sebastian","state":"Basque Country","zip":"20080","country":"Spain","geoPoint":{"lat":43.31283,"lon":-1.97499}},{"facility":"Novartis Investigative Site","city":"Badalona","state":"Catalonia","zip":"08916","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Novartis Investigative Site","city":"Barcelona","state":"Catalonia","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Novartis Investigative Site","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Novartis Investigative Site","city":"Las Palmas de Gran Canaria","zip":"35016","country":"Spain","geoPoint":{"lat":28.10178,"lon":-15.41573}},{"facility":"Novartis Investigative Site","city":"Madrid","zip":"28009","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Novartis Investigative Site","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Novartis Investigative Site","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Novartis Investigative Site","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Novartis Investigative Site","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Novartis Investigative Site","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Novartis Investigative Site","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"facility":"Novartis Investigative Site","city":"Stockholm","zip":"171 76","country":"Sweden","geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"Novartis Investigative Site","city":"Basel","zip":"4031","country":"Switzerland","geoPoint":{"lat":47.55839,"lon":7.57327}},{"facility":"Novartis Investigative Site","city":"Kaohsiung City","zip":"83301","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Novartis Investigative Site","city":"Tainan","zip":"704","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"Novartis Investigative Site","city":"Taipei","zip":"10002","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Novartis Investigative Site","city":"Taipei","zip":"11217","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Novartis Investigative Site","city":"Taoyuan District","zip":"333","country":"Taiwan","geoPoint":{"lat":24.9896,"lon":121.3187}},{"facility":"Novartis Investigative Site","city":"Songkhla","state":"Hat Yai","zip":"90110","country":"Thailand","geoPoint":{"lat":7.19882,"lon":100.5951}},{"facility":"Novartis Investigative Site","city":"Khon Kaen","state":"THA","zip":"40002","country":"Thailand","geoPoint":{"lat":16.44671,"lon":102.833}},{"facility":"Novartis Investigative Site","city":"Bangkok","zip":"10330","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Novartis Investigative Site","city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Novartis Investigative Site","city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Novartis Investigative Site","city":"Istanbul","state":"Bagcilar","zip":"34214","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Novartis Investigative Site","city":"Ankara","state":"Bilkent-Cankaya","zip":"6800","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Novartis Investigative Site","city":"Edirne","state":"Merkez","zip":"22030","country":"Turkey (Türkiye)","geoPoint":{"lat":41.67719,"lon":26.55597}},{"facility":"Novartis Investigative Site","city":"Ankara","state":"Sihhiye-Altindag","zip":"06230","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Novartis Investigative Site","city":"High Heaton","state":"Newcastle Upon Tyne","zip":"NE7 7DN","country":"United Kingdom","geoPoint":{"lat":54.99919,"lon":-1.58663}},{"facility":"Novartis Investigative Site","city":"London","zip":"NW3 2QG","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Novartis Investigative Site","city":"Manchester","zip":"M20 2BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"Novartis Investigative Site","city":"Plymouth","zip":"PL6 8DH","country":"United Kingdom","geoPoint":{"lat":50.37153,"lon":-4.14305}},{"facility":"Novartis Investigative Site","city":"Hanoi","zip":"100000","country":"Vietnam","geoPoint":{"lat":21.0245,"lon":105.84117}}]},"referencesModule":{"references":[{"pmid":"38039427","type":"DERIVED","citation":"Tan DSW, Felip E, de Castro G, Solomon BJ, Greystoke A, Cho BC, Cobo M, Kim TM, Ganguly S, Carcereny E, Paz-Ares L, Bennouna J, Garassino MC, Schenker M, Kim SW, Brase JC, Bury-Maynard D, Passos VQ, Deudon S, Dharan B, Song Y, Caparica R, Johnson BE. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. J Clin Oncol. 2024 Jan 10;42(2):192-204. doi: 10.1200/JCO.23.00980. Epub 2023 Dec 1."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\n\nThis trial data is currently available according to the process described on www.clinicalstudydatarequest.com."}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"All inclusion and exclusion criteria were checked at screening.","groups":[{"id":"FG000","title":"Part 1: Cohort A","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and pemetrexed."},{"id":"FG001","title":"Part 1: Cohort B","description":"Safety run-in, canakinumab in combination with pembrolizumab, cisplatin, and pemetrexed."},{"id":"FG002","title":"Part 1: Cohort C","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and paclitaxel."},{"id":"FG003","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"FG004","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"320"},{"groupId":"FG004","numSubjects":"323"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"320"},{"groupId":"FG004","numSubjects":"323"}]}],"dropWithdraws":[{"type":"Progressive disease","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"149"},{"groupId":"FG004","numSubjects":"148"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"19"},{"groupId":"FG004","numSubjects":"13"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"28"},{"groupId":"FG004","numSubjects":"29"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"35"},{"groupId":"FG004","numSubjects":"48"}]},{"type":"Subject decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"12"},{"groupId":"FG004","numSubjects":"12"}]},{"type":"No treated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"}]},{"type":"Treatment ongoing","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"76"},{"groupId":"FG004","numSubjects":"71"}]},{"type":"Guardian decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Part 1: Cohort A","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and pemetrexed."},{"id":"BG001","title":"Part 1: Cohort B","description":"Safety run-in, canakinumab in combination with pembrolizumab, cisplatin, and pemetrexed."},{"id":"BG002","title":"Part 1: Cohort C","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and paclitaxel."},{"id":"BG003","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"BG004","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"BG005","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"320"},{"groupId":"BG004","value":"323"},{"groupId":"BG005","value":"673"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64.5","spread":"6.57"},{"groupId":"BG001","value":"57.9","spread":"13.03"},{"groupId":"BG002","value":"63.1","spread":"7.18"},{"groupId":"BG003","value":"61.7","spread":"9.65"},{"groupId":"BG004","value":"62.7","spread":"8.74"},{"groupId":"BG005","value":"62.2","spread":"9.23"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"93"},{"groupId":"BG004","value":"91"},{"groupId":"BG005","value":"192"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"227"},{"groupId":"BG004","value":"232"},{"groupId":"BG005","value":"481"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"185"},{"groupId":"BG004","value":"180"},{"groupId":"BG005","value":"380"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"115"},{"groupId":"BG004","value":"117"},{"groupId":"BG005","value":"244"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"5"}]}]},{"title":"Multiple","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"2"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"20"},{"groupId":"BG005","value":"42"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Part 1 (Safety Run-in): Number of Participants With Dose-limiting Toxicities (DLTs)","description":"A DLT was defined as an adverse event or abnormal laboratory value assessed as unrelated to disease progression, inter-current illness, or concomitant medications that met certain criteria as defined in the protocol.","populationDescription":"The dose-determining set (DDS) included all participants from the safety set who met the minimum exposure criterion and had sufficient safety evaluations, or experienced a dose-limiting toxicity (DLT) during the first 42 days (6 weeks) of dosing. Data are reported for Part 1 only.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the first 42 days of dosing","groups":[{"id":"OG000","title":"Part 1: Cohort A","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and pemetrexed."},{"id":"OG001","title":"Part 1: Cohort B","description":"Safety run-in, canakinumab in combination with pembrolizumab, cisplatin, and pemetrexed."},{"id":"OG002","title":"Part 1: Cohort C","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and paclitaxel."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]}]},{"type":"PRIMARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Progression-free Survival (PFS) Per Investigator Assessment Using RECIST v1.1","description":"Progression free survival was defined as the time from randomization to the date of the first documented radiological progression using RECIST 1.1 (Response evaluation criteria in solid tumor) or death due to any cause.","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"18 months","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"323"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.77","lowerLimit":"5.62","upperLimit":"7.75"},{"groupId":"OG001","value":"6.77","lowerLimit":"5.52","upperLimit":"6.93"}]}]}]},{"type":"PRIMARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Overall Survival (OS) Per Investigator Assessment Using RECIST v1.1","description":"Overall survival is defined as the time from date of randomization to date of death due to any cause.","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to approximately 32 months","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"323"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.83","lowerLimit":"16.26","upperLimit":"NA","comment":"The upper limit of 95% CI was not estimable due to an insufficient number of participants with events."},{"groupId":"OG001","value":"20.17","lowerLimit":"16.23","upperLimit":"22.37"}]}]}]},{"type":"SECONDARY","title":"Part 1 (Safety Run-in): Overall Response Rate (ORR) Per Investigator Assessment Using RECIST v1.1","description":"ORR was defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Data are reported for Part 1 only.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Up to approximately 14 months","groups":[{"id":"OG000","title":"Part 1: Cohort A","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and pemetrexed."},{"id":"OG001","title":"Part 1: Cohort B","description":"Safety run-in, canakinumab in combination with pembrolizumab, cisplatin, and pemetrexed."},{"id":"OG002","title":"Part 1: Cohort C","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and paclitaxel."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"2.5","upperLimit":"55.6"},{"groupId":"OG001","value":"72.7","lowerLimit":"39.0","upperLimit":"94.0"},{"groupId":"OG002","value":"44.4","lowerLimit":"13.7","upperLimit":"78.8"}]}]}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Overall Response Rate (ORR) Per Investigator Assessment Using RECIST v1.1","description":"ORR was defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Up to approximately 26 months","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"323"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.6","lowerLimit":"40.1","upperLimit":"51.3"},{"groupId":"OG001","value":"45.5","lowerLimit":"40.0","upperLimit":"51.1"}]}]}]},{"type":"SECONDARY","title":"Part 1 (Safety run-in): Disease Control Rate (DCR) Per Investigator Assessment Using RECIST v1.1","description":"Disease control rate was defined as the percentage of participants with complete response (CR) or partial response (PR) or participants with stable disease (SD) as per investigator assessment according to RECIST 1.1 criteria. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters; SD=Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Data are reported for Part 1 only.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Up to approximately 14 months","groups":[{"id":"OG000","title":"Part 1: Cohort A","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and pemetrexed."},{"id":"OG001","title":"Part 1: Cohort B","description":"Safety run-in, canakinumab in combination with pembrolizumab, cisplatin, and pemetrexed."},{"id":"OG002","title":"Part 1: Cohort C","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and paclitaxel."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","lowerLimit":"34.8","upperLimit":"93.3"},{"groupId":"OG001","value":"81.8","lowerLimit":"48.2","upperLimit":"97.7"},{"groupId":"OG002","value":"77.8","lowerLimit":"40.0","upperLimit":"97.2"}]}]}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Disease Control Rate (DCR) Per Investigator Assessment Using RECIST v1.1","description":"Disease control rate was defined as the percentage of participants with complete response (CR) or partial response (PR) or participants with stable disease (SD) as per investigator assessment according to RECIST 1.1 criteria. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters; SD=Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Up to approximately 26 months","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"323"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","lowerLimit":"82.7","upperLimit":"90.4"},{"groupId":"OG001","value":"84.8","lowerLimit":"80.4","upperLimit":"88.6"}]}]}]},{"type":"SECONDARY","title":"Part 1 (Safety run-in): Duration of Response (DOR) Per Investigator Assessment Using RECIST v1.1","description":"Duration of response was defined as the time from first documented response of CR or PR to date of first documented progression or death due to any cause, according to RECIST 1.1 criteria. DOR only applied to participants whose best overall response was CR or PR based on tumor response data per local review. If a participant did not have an event, DOR was censored at the date of last adequate tumor assessment. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Participants who never achieved a best overall response of CR or PR were excluded from the analysis. Data are reported for responders in Part 1 only.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to approximately 25 months","groups":[{"id":"OG000","title":"Part 1: Cohort A","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and pemetrexed."},{"id":"OG001","title":"Part 1: Cohort B","description":"Safety run-in, canakinumab in combination with pembrolizumab, cisplatin, and pemetrexed."},{"id":"OG002","title":"Part 1: Cohort C","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and paclitaxel."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.43","lowerLimit":"4.93","upperLimit":"NA","comment":"The upper limit of 95% CI was not estimable due to an insufficient number of participants with events."},{"groupId":"OG001","value":"18.50","lowerLimit":"6.34","upperLimit":"NA","comment":"The upper limit of 95% CI was not estimable due to an insufficient number of participants with events."},{"groupId":"OG002","value":"8.15","lowerLimit":"5.55","upperLimit":"NA","comment":"The upper limit of 95% CI was not estimable due to an insufficient number of participants with events."}]}]}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Duration of Response (DOR) Per Investigator Assessment Using RECIST v1.1","description":"Duration of response was defined as the time from first documented response of CR or PR to date of first documented progression or death due to any cause, according to RECIST 1.1 criteria. DOR only applied to participants whose best overall response was CR or PR based on tumor response data per local review. If a participant did not have an event, DOR was censored at the date of last adequate tumor assessment. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Participants who never achieved a best overall response of CR or PR were excluded from the analysis. Data are reported for responders in Part 2 only.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to approximately 26 months","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"147"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.26","lowerLimit":"10.41","upperLimit":"NA","comment":"The upper limit of 95% CI was not estimable due to an insufficient number of participants with events."},{"groupId":"OG001","value":"13.60","lowerLimit":"10.32","upperLimit":"NA","comment":"The upper limit of 95% CI was not estimable due to an insufficient number of participants with events."}]}]}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Time to Response (TTR) Per Investigator Assessment Using RECIST v1.1","description":"Time to response (TTR) was defined as duration of time between the date of randomization and the date of first documented response of either CR or PR, according to RECIST 1.1 criteria. Duration of response was defined as the time from first documented response of CR or PR to date of first documented progression or death due to any cause, according to RECIST 1.1 criteria. CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Data are reported for responders in Part 2 only.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to approximately 26 months","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"147"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"8.94","upperLimit":"NA","comment":"The median and upper limit of 95% CI were not estimable due to an insufficient number of participants with events."},{"groupId":"OG001","value":"NA","lowerLimit":"4.99","upperLimit":"NA","comment":"The median and upper limit of 95% CI were not estimable due to an insufficient number of participants with events."}]}]}]},{"type":"SECONDARY","title":"Part 1 (Safety Run-in): Antidrug Antibodies (ADA) of Canakinumab","description":"Participants with at least one ADA-positive sample.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2028-06","timeFrame":"Predose (0 hours (h)) on Day 1 of Cycles 1, 4, 8, 12, 16 (Cycle length =21 days), at end of treatment & then at 26, 78 and 130 days after last dose","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Number of Participants With Antidrug Antibodies (ADA) of Canakinumab","description":"Participants with at least one ADA-positive sample.","populationDescription":"The safety set comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. The data analysis applied to the Part 2 Canakinumab+pembro+CTx arm only.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 26 months","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"320"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"On treatment","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}]},{"type":"SECONDARY","title":"Part 1 (Safety run-in): Antidrug Antibodies (ADAs) of Pembrolizumab","description":"Participants with at least one ADA-positive sample.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2028-06","timeFrame":"Predose (0 h) on Day 1 of Cycles 1, 2, 4, 8, 12, 16 (Cycle length =21 days), at end of treatment & then at 26 days after last dose","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Antidrug Antibodies (ADA) of Pembrolizumab","description":"Participants with at least one ADA-positive sample.","populationDescription":"The safety set comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 26 months","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"322"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"On treatment","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Part 1 (Safety Run-in): Serum Canakinumab Concentration","populationDescription":"The pharmacokinetic (PK) analysis set - canakinumab included all participants who received at least one dose of canakinumab and had at least one evaluable PK sample for canakinumab. Data are reported for Part 1 only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose (0 h) on Day 1 of Cycles 1-6, 8, 12, 16, Postdose on day 2, 8, 15 of Cycle 1, Post dose on Cycle 5 day 8, at end of treatment & then at 26, 78 and 130 days after last dose (Cycle length =21 days)","groups":[{"id":"OG000","title":"Part 1: Cohort A","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and pemetrexed."},{"id":"OG001","title":"Part 1: Cohort B","description":"Safety run-in, canakinumab in combination with pembrolizumab, cisplatin, and pemetrexed."},{"id":"OG002","title":"Part 1: Cohort C","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and paclitaxel."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}]}],"classes":[{"title":"Cycle 1, Day 1, 0 hour n=9,11,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"},{"groupId":"OG002","value":"0","spread":"0"}]}]},{"title":"Cycle 1, Day 1, 24 hour n=8,11,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.43","spread":"72.1"},{"groupId":"OG001","value":"4.97","spread":"113.5"},{"groupId":"OG002","value":"4.57","spread":"67.1"}]}]},{"title":"Cycle 1, Day 1, 168 hour n=9,11,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":"44.5"},{"groupId":"OG001","value":"14.0","spread":"61.7"},{"groupId":"OG002","value":"12.8","spread":"33.2"}]}]},{"title":"Cycle 1, Day 1, 336 hour n=8,10,8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":"35.0"},{"groupId":"OG001","value":"12.3","spread":"55.2"},{"groupId":"OG002","value":"10.9","spread":"35.9"}]}]},{"title":"Cycle 2, Day 1, 0 hour n=9,9,7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","spread":"33.6"},{"groupId":"OG001","value":"8.80","spread":"49.4"},{"groupId":"OG002","value":"8.69","spread":"34.5"}]}]},{"title":"Cycle 3, Day 1, 0 hour n=7,9,8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":"31.3"},{"groupId":"OG001","value":"20.3","spread":"40.3"},{"groupId":"OG002","value":"17.1","spread":"16.4"}]}]},{"title":"Cycle 4, Day 1, 0 hour n=8,8,6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":"29.0"},{"groupId":"OG001","value":"26.6","spread":"35.0"},{"groupId":"OG002","value":"19.4","spread":"29.2"}]}]},{"title":"Cycle 5, Day 1, 0 hour n=4,7,6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.9","spread":"41.8"},{"groupId":"OG001","value":"35.6","spread":"47.6"},{"groupId":"OG002","value":"22.4","spread":"39.0"}]}]},{"title":"Cycle 5, Day 1, 168 hour n=5,9,4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":"33.1"},{"groupId":"OG001","value":"49.8","spread":"42.5"},{"groupId":"OG002","value":"32.7","spread":"22.7"}]}]},{"title":"Cycle 6, Day 1, 0 hour n=3,7,6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.2","spread":"40.0"},{"groupId":"OG001","value":"36.8","spread":"47.8"},{"groupId":"OG002","value":"26.3","spread":"27.4"}]}]},{"title":"Cycle 8, Day 1, 0 hour n=3,7,4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":"27.5"},{"groupId":"OG001","value":"45.8","spread":"38.6"},{"groupId":"OG002","value":"29.9","spread":"29.6"}]}]},{"title":"Cycle 12, Day 1, 0 hour n=2,6,4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":"90.4"},{"groupId":"OG001","value":"52.2","spread":"42.9"},{"groupId":"OG002","value":"32.4","spread":"41.0"}]}]},{"title":"Cycle 16, Day 1, 0 hour n=1,5,4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.2","spread":"0"},{"groupId":"OG001","value":"41.8","spread":"67.3"},{"groupId":"OG002","value":"31.0","spread":"35.0"}]}]}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Serum Canakinumab Concentration","populationDescription":"The pharmacokinetic (PK) analysis set - canakinumab included all participants who received at least one dose of canakinumab and had at least one evaluable PK sample for canakinumab. Data are reported for the Part 2 Canakinumab+pembro+CTx arm only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose (0 h) on Day 1 of Cycles 1-6, 8, 12, 16, Postdose on day 2, 8, 15 of Cycle 1, Post dose on Cycle 5 day 8, at end of treatment & then at 26, 78 and 130 days after last dose (Cycle length =21 days)","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"302"}]}],"classes":[{"title":"Cycle 1, Day 1, 0 hour n=291","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"291"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"}]}]},{"title":"Cycle 1, Day 1, 24 hour n=263","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"263"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.36","spread":"99.3"}]}]},{"title":"Cycle 1, Day 1, 168 hour n=271","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"271"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":"52.1"}]}]},{"title":"Cycle 1, Day 1, 336 hour n=272","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"272"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":"47.2"}]}]},{"title":"Cycle 2, Day 1, 0 hour n=228","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"228"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.82","spread":"46.8"}]}]},{"title":"Cycle 3, Day 1, 0 hour n=181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":"40.1"}]}]},{"title":"Cycle 4, Day 1, 0 hour n=166","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"166"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":"44.4"}]}]},{"title":"Cycle 5, Day 1, 0 hour n=154","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"154"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":"42.9"}]}]},{"title":"Cycle 5, Day 1, 168 hour n=174","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"174"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":"42.2"}]}]},{"title":"Cycle 6, Day 1, 0 hour n=181","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":"47.5"}]}]},{"title":"Cycle 8, Day 1, 0 hour n=144","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":"46.9"}]}]},{"title":"Cycle 12, Day 1, 0 hour n=124","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":"49.8"}]}]},{"title":"Cycle 16, Day 1, 0 hour n=91","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.0","spread":"49.0"}]}]}]},{"type":"SECONDARY","title":"Part 1 (Safety Run-in): Serum Pembrolizumab Concentration","populationDescription":"The pharmacokinetic (PK) analysis set -pembrolizumab included all participants who received at least one dose of pembrolizumab and had at least one evaluable PK sample for pembrolizumab. Data are reported for Part 1 only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose (0 h) on Day 1 of Cycles 1-6, 8, 12, 16, Postdose on day 2, 8, 15 of Cycle 1, at end of treatment & then at 26 days after last dose (Cycle length =21 days)","groups":[{"id":"OG000","title":"Part 1: Cohort A","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and pemetrexed."},{"id":"OG001","title":"Part 1: Cohort B","description":"Safety run-in, canakinumab in combination with pembrolizumab, cisplatin, and pemetrexed."},{"id":"OG002","title":"Part 1: Cohort C","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and paclitaxel."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}]}],"classes":[{"title":"Cycle 1, Day 1, 0 hour n=9,11,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"},{"groupId":"OG002","value":"0","spread":"0"}]}]},{"title":"Cycle 1, Day 1, end-of-infusion, n=9,11,7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.9","spread":"29.8"},{"groupId":"OG001","value":"52.9","spread":"41.9"},{"groupId":"OG002","value":"48.1","spread":"17.7"}]}]},{"title":"Cycle 1, Day 1, 24 hour n=7,11,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.5","spread":"26.7"},{"groupId":"OG001","value":"43.0","spread":"35.1"},{"groupId":"OG002","value":"41.4","spread":"23.4"}]}]},{"title":"Cycle 1, Day 1, 168 hour n=9,11,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":"49.4"},{"groupId":"OG001","value":"21.7","spread":"42.9"},{"groupId":"OG002","value":"18.7","spread":"17.3"}]}]},{"title":"Cycle 1, Day 1, 336 hour n=9,11,8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":"28.8"},{"groupId":"OG001","value":"14.7","spread":"40.6"},{"groupId":"OG002","value":"12.5","spread":"25.5"}]}]},{"title":"Cycle 2, Day 1, 0 hour n=9,9,7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":"36.3"},{"groupId":"OG001","value":"14.5","spread":"49.2"},{"groupId":"OG002","value":"10.5","spread":"13.0"}]}]},{"title":"Cycle 3, Day 1, 0 hour n=7,9,7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.0","spread":"38.2"},{"groupId":"OG001","value":"22.5","spread":"46.8"},{"groupId":"OG002","value":"15.5","spread":"27.2"}]}]},{"title":"Cycle 4, Day 1, 0 hour n=8,8,6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":"31.4"},{"groupId":"OG001","value":"33.0","spread":"108.5"},{"groupId":"OG002","value":"23.5","spread":"37.2"}]}]},{"title":"Cycle 5, Day 1, 0 hour n=5,7,6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":"31.9"},{"groupId":"OG001","value":"35.5","spread":"44.3"},{"groupId":"OG002","value":"28.5","spread":"82.0"}]}]},{"title":"Cycle 5, Day 1, end-of-infusion n=5,7,5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.7","spread":"19.7"},{"groupId":"OG001","value":"99.3","spread":"29.6"},{"groupId":"OG002","value":"57.4","spread":"51.5"}]}]},{"title":"Cycle 6, Day 1, 0 hour n=2,7,5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":"68.8"},{"groupId":"OG001","value":"37.0","spread":"33.6"},{"groupId":"OG002","value":"26.6","spread":"31.2"}]}]},{"title":"Cycle 8, Day 1, 0 hour n=3,7,3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.4","spread":"16.2"},{"groupId":"OG001","value":"45.3","spread":"43.8"},{"groupId":"OG002","value":"35.0","spread":"52.0"}]}]},{"title":"Cycle 12, Day 1, 0 hour n=1,7,1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"76.1","spread":"0"},{"groupId":"OG001","value":"42.9","spread":"68.8"},{"groupId":"OG002","value":"20.5","spread":"0"}]}]},{"title":"Cycle 16, Day 1, 0 hour n=1,5,1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":"0"},{"groupId":"OG001","value":"43.4","spread":"84.5"},{"groupId":"OG002","value":"27.2","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Serum Pembrolizumab Concentration","populationDescription":"The pharmacokinetic (PK) analysis set -pembrolizumab included all participants who received at least one dose of pembrolizumab and had at least one evaluable PK sample for pembrolizumab. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose (0 h) on Day 1 of Cycles 1-6, 8, 12, 16, Postdose on day 2, 8, 15 of Cycle 1, at end of treatment & then at 26 days after last dose (Cycle length =21 days)","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"36"}]}],"classes":[{"title":"Cycle 1, Day 1, 0 hours n=29,28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]},{"title":"Cycle 1, Day 1, end-of-infusion, n=27,27","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":"55.1"},{"groupId":"OG001","value":"50.9","spread":"36.0"}]}]},{"title":"Cycle 1, Day 1, 24 hours n=29,31","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.9","spread":"23.6"},{"groupId":"OG001","value":"43.7","spread":"51.8"}]}]},{"title":"Cycle 1, Day 1, 168 hours n=28,29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":"30.1"},{"groupId":"OG001","value":"21.4","spread":"42.2"}]}]},{"title":"Cycle 1, Day 1, 336 hours n=23,25","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":"33.8"},{"groupId":"OG001","value":"14.9","spread":"39.9"}]}]},{"title":"Cycle 2, Day 1, 0 hours n=19,25","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":"46.6"},{"groupId":"OG001","value":"12.9","spread":"39.3"}]}]},{"title":"Cycle 3, Day 1, 0 hours n=12,20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":"39.8"},{"groupId":"OG001","value":"20.6","spread":"50.0"}]}]},{"title":"Cycle 4, Day 1, 0 hours n=12,20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.7","spread":"42.5"},{"groupId":"OG001","value":"27.2","spread":"55.0"}]}]},{"title":"Cycle 5, Day 1, 0 hours n=15,22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":"38.6"},{"groupId":"OG001","value":"26.5","spread":"55.0"}]}]},{"title":"Cycle 5, Day 1, end-of-infusion n=18,21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.3","spread":"42.6"},{"groupId":"OG001","value":"70.9","spread":"41.5"}]}]},{"title":"Cycle 6, Day 1, 0 hours n=14,17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.0","spread":"69.0"},{"groupId":"OG001","value":"32.2","spread":"71.5"}]}]},{"title":"Cycle 8, Day 1, 0 hours n=16,17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.0","spread":"53.2"},{"groupId":"OG001","value":"30.1","spread":"57.4"}]}]},{"title":"Cycle 12, Day 1, 0 hours n=10,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":"27.6"},{"groupId":"OG001","value":"41.9","spread":"44.7"}]}]},{"title":"Cycle 16, Day 1, 0 hours n=9,8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":"39.4"},{"groupId":"OG001","value":"47.0","spread":"38.0"}]}]}]},{"type":"SECONDARY","title":"Part 1 (Safety Run-in): Plasma Pemetrexed Concentration","populationDescription":"The pharmacokinetic (PK) analysis set -pemetrexed included all participants who received at least one dose of pemetrexed and had at least one evaluable PK sample for pemetrexed. Data are reported for the Part 1 Cohorts A and B arms only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose (0 h) and end of infusion on Cycle 1 and 2; 1, 4, 8 h post infusion on Cycle 1; 1, 2, 4, 8h post infusion on Cycle 2 (Cycle length =21 days)","groups":[{"id":"OG000","title":"Part 1: Cohort A","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and pemetrexed."},{"id":"OG001","title":"Part 1: Cohort B","description":"Safety run-in, canakinumab in combination with pembrolizumab, cisplatin, and pemetrexed."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"classes":[{"title":"Cycle 1, Day 1, Pre-infusion n=9,11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"517","spread":"1.4"}]}]},{"title":"Cycle 1, Day 1, end-of-infusion, n=9,11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"102000","spread":"30.2"},{"groupId":"OG001","value":"87800","spread":"39.5"}]}]},{"title":"Cycle 1, Day 1, 1 hour n=9,11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39000","spread":"23.3"},{"groupId":"OG001","value":"39000","spread":"29.5"}]}]},{"title":"Cycle 1, Day 1, 4 hours n=9,11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10300","spread":"25.1"},{"groupId":"OG001","value":"10300","spread":"29.6"}]}]},{"title":"Cycle 1, Day 1, 8 hours n=9,11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3180","spread":"38.3"},{"groupId":"OG001","value":"2340","spread":"58.8"}]}]},{"title":"Cycle 2, Day 1, Pre-infusion n=8,10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]},{"title":"Cycle 2, Day 1, End-of-infusion n=9,10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93300","spread":"19.0"},{"groupId":"OG001","value":"92600","spread":"37.5"}]}]},{"title":"Cycle 2, Day 1, 1 hour n=9,10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43600","spread":"15.7"},{"groupId":"OG001","value":"43500","spread":"16.2"}]}]},{"title":"Cycle 2, Day 1, 2 hours n=9,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26300","spread":"19.1"},{"groupId":"OG001","value":"23400","spread":"13.9"}]}]},{"title":"Cycle 2, Day 1, 4 hours n=9,10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11100","spread":"25.5"},{"groupId":"OG001","value":"10800","spread":"34.3"}]}]},{"title":"Cycle 2, Day 1, 8 hours n=9,10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3920","spread":"39.1"},{"groupId":"OG001","value":"2760","spread":"55.0"}]}]}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Pemetrexed Concentration","populationDescription":"The pharmacokinetic (PK) analysis set -pemetrexed included all participants who received at least one dose of pemetrexed and had at least one evaluable PK sample for pemetrexed. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose (0 h) and end of infusion on Cycle 1 and 2; 1, 4, 8 h post infusion on Cycle 1; 1, 2, 4, 8h post infusion on Cycle 2 (Cycle length =21 days)","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"}]}],"classes":[{"title":"Cycle 1, Day 1, Pre-infusion n=18,18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]},{"title":"Cycle 1, Day 1, end-of-infusion, n=19,20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"92000","spread":"21.9"},{"groupId":"OG001","value":"86400","spread":"46.6"}]}]},{"title":"Cycle 1, Day 1, 1 hour n=19,20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42900","spread":"23.5"},{"groupId":"OG001","value":"36900","spread":"29.4"}]}]},{"title":"Cycle 1, Day 1, 4 hours n=19,20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11700","spread":"33.3"},{"groupId":"OG001","value":"9390","spread":"48.5"}]}]},{"title":"Cycle 2, Day 1, Pre-infusion n=15,16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]},{"title":"Cycle 2, Day 1, End-of-infusion n=15,17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"89200","spread":"40.8"},{"groupId":"OG001","value":"97000","spread":"32.3"}]}]},{"title":"Cycle 2, Day 1, 1 hour n=15,17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47600","spread":"30.9"},{"groupId":"OG001","value":"37300","spread":"20.6"}]}]},{"title":"Cycle 2, Day 1, 2 hours n=15,17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26900","spread":"28.7"},{"groupId":"OG001","value":"20900","spread":"41.9"}]}]},{"title":"Cycle 2, Day 1, 4 hours n=14,17","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12500","spread":"38.2"},{"groupId":"OG001","value":"9880","spread":"55.8"}]}]}]},{"type":"SECONDARY","title":"Part 1 (Safety Run-in): Plasma Cisplatin Concentration","populationDescription":"The pharmacokinetic (PK) analysis set -cisplatin included all participants who received at least one dose of cisplatin and had at least one evaluable PK sample for cisplatin. Data are reported for the Part 1 Cohort B arm only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose (0 h) and end of infusion on Cycle 1 and 2; 2, 4, 8 h post infusion on Cycle 1; 1.5, 2, 4, 8 h post infusion on Cycle 2 (Cycle length =21 days)","groups":[{"id":"OG000","title":"Part 1: Cohort B","description":"Safety run-in, canakinumab in combination with pembrolizumab, cisplatin, and pemetrexed."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"classes":[{"title":"Cycle 1, Day 1, Pre-infusion n=11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"}]}]},{"title":"Cycle 1, Day 1, end-of-infusion, n=11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3750","spread":"130.2"}]}]},{"title":"Cycle 1, Day 1, 2 hours n=6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3690","spread":"248.2"}]}]},{"title":"Cycle 1, Day 1, 4 hours n=11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1930","spread":"35.9"}]}]},{"title":"Cycle 1, Day 1, 8 hours n=11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1680","spread":"22.4"}]}]},{"title":"Cycle 2, Day 1, Pre-infusion n=10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"235","spread":"29.3"}]}]},{"title":"Cycle 2, Day 1, End-of-infusion n=10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2900","spread":"45.6"}]}]},{"title":"Cycle 2, Day 1, 1.5 hours n=10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2100","spread":"51.9"}]}]},{"title":"Cycle 2, Day 1, 2 hours n=5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2650","spread":"20.3"}]}]},{"title":"Cycle 2, Day 1, 4 hours n=10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2070","spread":"15.2"}]}]},{"title":"Cycle 2, Day 1, 8 hours n=10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1750","spread":"29.9"}]}]}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Cisplatin Concentration","populationDescription":"The pharmacokinetic (PK) analysis set -cisplatin included all participants who received at least one dose of cisplatin and had at least one evaluable PK sample for cisplatin. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose (0 h) and end of infusion on Cycle 1 and 2; 2, 4, 8 h post infusion on Cycle 1; 1.5, 2, 4, 8 h post infusion on Cycle 2 (Cycle length = 21 days)","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"19"}]}],"classes":[{"title":"Cycle 1, Day 1, Pre-infusion n=21,18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"177","spread":"47.5"}]}]},{"title":"Cycle 1, Day 1, end-of-infusion, n=20,18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3670","spread":"49.6"},{"groupId":"OG001","value":"3120","spread":"20.9"}]}]},{"title":"Cycle 1, Day 1, 2 hours n=17,18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2280","spread":"27.8"},{"groupId":"OG001","value":"2180","spread":"23.5"}]}]},{"title":"Cycle 1, Day 1, 4 hours n=17,16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1950","spread":"11.2"},{"groupId":"OG001","value":"1950","spread":"17.5"}]}]},{"title":"Cycle 2, Day 1, Pre-infusion n=20,14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"288","spread":"58.9"},{"groupId":"OG001","value":"296","spread":"51.7"}]}]},{"title":"Cycle 2, Day 1, End-of-infusion n=19,13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3130","spread":"92.0"},{"groupId":"OG001","value":"2820","spread":"88.2"}]}]},{"title":"Cycle 2, Day 1, 1.5 hours n=16,12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2790","spread":"29.9"},{"groupId":"OG001","value":"2410","spread":"38.3"}]}]},{"title":"Cycle 2, Day 1, 2 hours n=16,12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2550","spread":"22.7"},{"groupId":"OG001","value":"2790","spread":"23.9"}]}]},{"title":"Cycle 2, Day 1, 4 hours n=19,11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2340","spread":"17.4"},{"groupId":"OG001","value":"2340","spread":"13.7"}]}]}]},{"type":"SECONDARY","title":"Part 1 (Safety Run-in): Plasma Carboplatin Concentration","populationDescription":"The pharmacokinetic (PK) analysis set -carboplatin included all participants who received at least one dose of carboplatin and had at least one evaluable PK sample for carboplatin. Data are reported for the Part 1 Cohorts A and C arms only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose (0 h), end of infusion, 1, 2, 4, 8 h post infusion on Cycles 1 and 2 (Cycle length =21 days)","groups":[{"id":"OG000","title":"Part 1: Cohort A","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and pemetrexed."},{"id":"OG001","title":"Part 1: Cohort C","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and paclitaxel."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"classes":[{"title":"Cycle 1, Day 1, Pre-infusion n=8,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]},{"title":"Cycle 1, Day 1, End-of-infusion, n=9,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17400","spread":"21.9"},{"groupId":"OG001","value":"21700","spread":"49.8"}]}]},{"title":"Cycle 1, Day 1, 1 hour n=9,6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10400","spread":"42.7"},{"groupId":"OG001","value":"13300","spread":"46.8"}]}]},{"title":"Cycle 1, Day 1, 2 hours n=9,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6200","spread":"34.3"},{"groupId":"OG001","value":"7380","spread":"23.5"}]}]},{"title":"Cycle 1, Day 1, 4 hours n=9,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3380","spread":"34.6"},{"groupId":"OG001","value":"3970","spread":"29.4"}]}]},{"title":"Cycle 1, Day 1, 8 hours n=9,6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1370","spread":"33.6"},{"groupId":"OG001","value":"1540","spread":"39.6"}]}]},{"title":"Cycle 2, Day 1, Pre-infusion n=9,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":"29.7"},{"groupId":"OG001","value":"120","spread":"16.4"}]}]},{"title":"Cycle 2, Day 1, End-of-infusion n=9,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10300","spread":"441.8"},{"groupId":"OG001","value":"16200","spread":"32.4"}]}]},{"title":"Cycle 2, Day 1, 1 hour n=8,6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13300","spread":"44.1"},{"groupId":"OG001","value":"11400","spread":"24.5"}]}]},{"title":"Cycle 2, Day 1, 2 hours n=9,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8080","spread":"38.5"},{"groupId":"OG001","value":"6620","spread":"22.5"}]}]},{"title":"Cycle 2, Day 1, 4 hours n=9,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3590","spread":"26.8"},{"groupId":"OG001","value":"3680","spread":"26.7"}]}]},{"title":"Cycle 2, Day 1, 8 hours n=9,5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1670","spread":"29.7"},{"groupId":"OG001","value":"1800","spread":"34.8"}]}]}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Carboplatin Concentration","populationDescription":"The pharmacokinetic (PK) analysis set -carboplatin included all participants who received at least one dose of carboplatin and had at least one evaluable PK sample for carboplatin. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose (0 h), end of infusion, 1, 2, 4, 8 h post infusion on Cycles 1 and 2 (Cycle length =21 days)","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"23"}]}],"classes":[{"title":"Cycle 1, Day 1, Pre-infusion n=17,19","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"668","spread":"0"}]}]},{"title":"Cycle 1, Day 1, End-of-infusion, n=17,23","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13800","spread":"23.4"},{"groupId":"OG001","value":"16900","spread":"53.6"}]}]},{"title":"Cycle 1, Day 1, 1 hour n=14,21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9980","spread":"40.4"},{"groupId":"OG001","value":"10600","spread":"35.9"}]}]},{"title":"Cycle 1, Day 1, 2 hours n=17,23","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7250","spread":"25.0"},{"groupId":"OG001","value":"6930","spread":"36.3"}]}]},{"title":"Cycle 1, Day 1, 4 hours n=16,22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3690","spread":"26.4"},{"groupId":"OG001","value":"3780","spread":"46.7"}]}]},{"title":"Cycle 2, Day 1, Pre-infusion n=11,16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":"37.2"},{"groupId":"OG001","value":"121","spread":"8.6"}]}]},{"title":"Cycle 2, Day 1, End-of-infusion n=11,18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14300","spread":"34.8"},{"groupId":"OG001","value":"13000","spread":"183.5"}]}]},{"title":"Cycle 2, Day 1, 1 hour n=10,16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8880","spread":"23.8"},{"groupId":"OG001","value":"9490","spread":"213.7"}]}]},{"title":"Cycle 2, Day 1, 2 hours n=12,18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6810","spread":"35.3"},{"groupId":"OG001","value":"7080","spread":"26.5"}]}]},{"title":"Cycle 2, Day 1, 4 hours n=11,18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3990","spread":"34.4"},{"groupId":"OG001","value":"3830","spread":"37.4"}]}]}]},{"type":"SECONDARY","title":"Part 1 (Safety Run-in): Plasma Paclitaxel Concentration","populationDescription":"The pharmacokinetic (PK) analysis set -paclitaxel included all participants who received at least one dose of paclitaxel and had at least one evaluable PK sample for paclitaxel. Data are reported for the Part 1 Cohort C arm only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose (0 h) and end of infusion on Cycle 1 and 2; 4, 8, 12 h post infusion on Cycle 1; 4, 6, 8, 12 h post infusion on Cycle 2 (Cycle length =21 days)","groups":[{"id":"OG000","title":"Part 1: Cohort C","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and paclitaxel."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"classes":[{"title":"Cycle 1, Day 1, Pre-infusion n=9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"}]}]},{"title":"Cycle 1, Day 1, End-of-infusion, n=9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4440","spread":"42.5"}]}]},{"title":"Cycle 1, Day 1, 4 hours n=8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"827","spread":"111.3"}]}]},{"title":"Cycle 1, Day 1, 8 hours n=9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"310","spread":"83.5"}]}]},{"title":"Cycle 1, Day 1, 12 hours n=6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":"78.3"}]}]},{"title":"Cycle 2, Day 1, Pre-infusion n=7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"}]}]},{"title":"Cycle 2, Day 1, End-of-infusion n=7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4940","spread":"35.1"}]}]},{"title":"Cycle 2, Day 1, 4 hours n=7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1090","spread":"89.5"}]}]},{"title":"Cycle 2, Day 1, 6 hours n=8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"525","spread":"74.1"}]}]},{"title":"Cycle 2, Day 1, 8 hours n=7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"333","spread":"79.8"}]}]},{"title":"Cycle 2, Day 1, 12 hours n=4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":"89.7"}]}]}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Paclitaxel Concentration","populationDescription":"The pharmacokinetic (PK) analysis set -paclitaxel included all participants who received at least one dose of paclitaxel and had at least one evaluable PK sample for paclitaxel. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose (0 h) and end of infusion on Cycle 1 and 2; 4, 8, 12 h post infusion on Cycle 1; 4, 6, 8, 12 h post infusion on Cycle 2 (Cycle length =21 days)","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"13"}]}],"classes":[{"title":"Cycle 1, Day 1, Pre-infusion n=12,11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]},{"title":"Cycle 1, Day 1, End-of-infusion, n=13,12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4620","spread":"97.3"},{"groupId":"OG001","value":"3380","spread":"116.8"}]}]},{"title":"Cycle 1, Day 1, 4 hours n=12,11","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1880","spread":"43.5"},{"groupId":"OG001","value":"1900","spread":"88.4"}]}]},{"title":"Cycle 1, Day 1, 24 hours n=10,8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":"38.9"},{"groupId":"OG001","value":"114","spread":"47.4"}]}]},{"title":"Cycle 2, Day 1, Pre-infusion n=9,8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]},{"title":"Cycle 2, Day 1, End-of-infusion n=10,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3930","spread":"41.8"},{"groupId":"OG001","value":"3660","spread":"75.1"}]}]},{"title":"Cycle 2, Day 1, 4 hours n=9,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1450","spread":"26.6"},{"groupId":"OG001","value":"1180","spread":"62.6"}]}]},{"title":"Cycle 2, Day 1, 6 hours n=7,8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"920","spread":"45.7"},{"groupId":"OG001","value":"775","spread":"55.0"}]}]},{"title":"Cycle 2, Day 1, 24 hours n=10,7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":"23.6"},{"groupId":"OG001","value":"81.4","spread":"27.7"}]}]}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Plasma Nab-paclitaxel Concentration","populationDescription":"The pharmacokinetic (PK) analysis set -nab-paclitaxel included all participants who received at least one dose of nab-paclitaxel and had at least one evaluable PK sample for nab-paclitaxel. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose (0 h) and end of infusion on Cy 1 and 2, 4, 8, 12 h post infusion on Cy 1, 4, 6, 8, 12 h post infusion on Cy 2 (Cy length =21 days)","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"15"}]}],"classes":[{"title":"Cycle 1, Day 1, Pre-infusion n=9,13","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]},{"title":"Cycle 1, Day 1, End-of-infusion, n=10,15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2620","spread":"87.5"},{"groupId":"OG001","value":"2520","spread":"285.4"}]}]},{"title":"Cycle 1, Day 1, 4 hours n=10,14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":"38.3"},{"groupId":"OG001","value":"117","spread":"90.2"}]}]},{"title":"Cycle 1, Day 1, 24 hours n=4,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":"16.7"},{"groupId":"OG001","value":"23.9","spread":"47.8"}]}]},{"title":"Cycle 2, Day 1, Pre-infusion n=7,8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"44.6","spread":"160.1"}]}]},{"title":"Cycle 2, Day 1, End-of-infusion n=7,8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1630","spread":"92.1"},{"groupId":"OG001","value":"3440","spread":"79.1"}]}]},{"title":"Cycle 2, Day 1, 4 hours n=6,8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.6","spread":"45.5"},{"groupId":"OG001","value":"96.5","spread":"63.8"}]}]},{"title":"Cycle 2, Day 1, 6 hours n=6,8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.6","spread":"47.1"},{"groupId":"OG001","value":"86.1","spread":"55.2"}]}]},{"title":"Cycle 2, Day 1, 24 hours n=5,7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":"107.7"},{"groupId":"OG001","value":"23.6","spread":"39.2"}]}]}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Time to Definitive 10-point Deterioration (TTDD) Symptom Scores of Pain, Cough and Dyspnea Per EORTC QLQ-LC13 Questionnaire","description":"The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) comprises both multi-item and single-item measures of lung cancer-associated symptoms (ie, coughing, dyspnea, and chest pain). Scores for each scale and single-item range from 0 to 100, with higher scores indicating higher level of symptoms. TTDD for chest pain, cough and dyspnea was defined as the time from randomization to the date of event, which was defined as at least 10 points absolute worsening from baseline of the corresponding scale score, with no later change below this threshold ie.\\<10 points was observed, or if this worsening was observed at the last assessment for the subject, or death due to any cause (whichever occurred earlier). If a subject did not have an event, TTDD was censored at the last adequate assessment.","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to approximately 25 months","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"323"}]}],"classes":[{"title":"Chest Pain n=65,96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"The median and lower and upper limit of 95% CI were not estimable due to an insufficient number of participants with events."},{"groupId":"OG001","value":"22.14","lowerLimit":"18.40","upperLimit":"NA","comment":"The upper limit of 95% CI was not estimable due to an insufficient number of participants with events."}]}]},{"title":"Cough n=63,94","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"94"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"The median and lower and upper limit of 95% CI were not estimable due to an insufficient number of participants with events."},{"groupId":"OG001","value":"23.06","lowerLimit":"17.51","upperLimit":"NA","comment":"The upper limit of 95% CI was not estimable due to an insufficient number of participants with events."}]}]},{"title":"Dyspnea n=111,149","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"149"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.61","lowerLimit":"13.50","upperLimit":"NA","comment":"The upper limit of 95% CI was not estimable due to an insufficient number of participants with events."},{"groupId":"OG001","value":"11.50","lowerLimit":"7.66","upperLimit":"15.90"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Chest pain","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Nominal p-values are presented without any statistical inference since there was no adjustment for multiplicity.","pValue":"0.00164","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.62","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.45","ciUpperLimit":"0.86"},{"groupIds":["OG000","OG001"],"groupDescription":"Cough","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Nominal p-values are presented without any statistical inference since there was no adjustment for multiplicity.","pValue":"0.00069","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.59","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.43","ciUpperLimit":"0.82"},{"groupIds":["OG000","OG001"],"groupDescription":"Dyspnea","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Nominal p-values are presented without any statistical inference since there was no adjustment for multiplicity.","pValue":"0.00045","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.51","ciUpperLimit":"0.84"}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Time to Definitive Deterioration in Global Health Status/Quality of Life, Shortness of Breath and Pain Per EORTC QLQ-C30 Questionnaire","description":"The European Organization for Research and Treatment of Cancer quality of life (EORTC QLQ-C30) is a questionnaire developed to assess the health-related quality of life of cancer participants. It assesses 15 domains consisting of 5 functional domains (physical, role, emotional, cognitive, social) and 9 symptom domains (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties) and a global health status/QoL scale. All domain scores range from 0 to 100. A high score for the functional or global health status scales indicates a high level of functioning or QoL; a high score for a symptom scale indicates a high level of symptoms.","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to approximately 25 months","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"323"}]}],"classes":[{"title":"Quality of Life n=119, 129","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"129"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.54","lowerLimit":"14.06","upperLimit":"NA","comment":"The upper limit of 95% CI was not estimable due to an insufficient number of participants with events."},{"groupId":"OG001","value":"15.90","lowerLimit":"11.40","upperLimit":"20.04"}]}]},{"title":"Shortness of Breath n=83,115","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"115"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"The median and lower and upper limits of 95% CI were not estimable due to an insufficient number of participants with events."},{"groupId":"OG001","value":"19.29","lowerLimit":"14.13","upperLimit":"21.62"}]}]},{"title":"Pain n=117,122","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.07","lowerLimit":"13.24","upperLimit":"NA","comment":"The upper limit of 95% CI was not estimable due to an insufficient number of participants with events."},{"groupId":"OG001","value":"17.91","lowerLimit":"12.65","upperLimit":"22.11"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Quality of Life","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Nominal p-values are presented without any statistical inference since there was no adjustment for multiplicity.","pValue":"0.113","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.66","ciUpperLimit":"1.10"},{"groupIds":["OG000","OG001"],"groupDescription":"Shortness of Breath","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Nominal p-values are presented without any statistical inference since there was no adjustment for multiplicity.","pValue":"0.00433","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.68","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.51","ciUpperLimit":"0.91"},{"groupIds":["OG000","OG001"],"groupDescription":"Pain","nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Nominal p-values are presented without any statistical inference since there was no adjustment for multiplicity.","pValue":"0.294","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.93","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.72","ciUpperLimit":"1.20"}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Change From Baseline in Score as Per the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Questionnaire","description":"The EQ-5D-5L questionnaire is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L measures 5 items on mobility, self-care, usual activities, pain/discomfort, anxiety/depression, measured on 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. A utility index can be computed from the EQ 5D-5L descriptive system with utility scores ranging from -0.281 (worst imaginable health state) to 1 (best imaginable health state), with -0.281 representing an \"unconscious\" health state. A single index value is analyzed for the EQ-5D-5L score. An increase from baseline in the EQ-ED-5L utility index is indicative of an improvement.). CFB = change from baseline","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Assessed every 3 weeks from Week 3 through Week 108, at follow-up visits 1, 2, 3, 4, and 5 (follow-up visits occurred every 26 days from week 108), and at 7 and 28 days post-disease progression, all up to a maximum of 3.5 years","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"323"}]}],"classes":[{"title":"CFB at Week 3 n=254,249","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"254"},{"groupId":"OG001","value":"249"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.766","spread":"0.2138"},{"groupId":"OG001","value":"0.768","spread":"0.2153"}]}]},{"title":"CFB at Week 6 n=236,230","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"236"},{"groupId":"OG001","value":"230"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.029","spread":"0.2135"},{"groupId":"OG001","value":"0.032","spread":"0.2317"}]}]},{"title":"CFB at Week 9 n=220,219","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"219"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.019","spread":"0.2074"},{"groupId":"OG001","value":"0.059","spread":"0.2512"}]}]},{"title":"CFB at Week 12 n=192,214","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"192"},{"groupId":"OG001","value":"214"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.028","spread":"0.2101"},{"groupId":"OG001","value":"0.044","spread":"0.2486"}]}]},{"title":"CFB at Week 15 n=194,196","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.031","spread":"0.2103"},{"groupId":"OG001","value":"0.039","spread":"0.2512"}]}]},{"title":"CFB at Week 18 n=187,198","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"198"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.020","spread":"0.2192"},{"groupId":"OG001","value":"0.050","spread":"0.2723"}]}]},{"title":"CFB at Week 21 n=173,176","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"176"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.016","spread":"0.2291"},{"groupId":"OG001","value":"0.041","spread":"0.2533"}]}]},{"title":"CFB at Week 24 n=160,164","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.027","spread":"0.2062"},{"groupId":"OG001","value":"0.050","spread":"0.2824"}]}]},{"title":"CFB at Week 27 n=157,155","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"155"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.020","spread":"0.1929"},{"groupId":"OG001","value":"0.043","spread":"0.2828"}]}]},{"title":"CFB at Week 30 n=140,145","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"145"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.047","spread":"0.1928"},{"groupId":"OG001","value":"0.046","spread":"0.2897"}]}]},{"title":"CFB at Week 33 n=136,124","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"124"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.036","spread":"0.1996"},{"groupId":"OG001","value":"0.055","spread":"0.2595"}]}]},{"title":"CFB at Week 36 n=129,119","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"119"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.061","spread":"0.1767"},{"groupId":"OG001","value":"0.054","spread":"0.2881"}]}]},{"title":"CFB at Week 39 n=133,119","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"119"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.037","spread":"0.2015"},{"groupId":"OG001","value":"0.071","spread":"0.2816"}]}]},{"title":"CFB at Week 42 n=124,102","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"102"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.044","spread":"0.1794"},{"groupId":"OG001","value":"0.063","spread":"0.2680"}]}]},{"title":"CFB at Week 45 n=124,100","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"100"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.035","spread":"0.1961"},{"groupId":"OG001","value":"0.065","spread":"0.2584"}]}]},{"title":"CFB at Week 48 n=111,105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"105"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.056","spread":"0.1870"},{"groupId":"OG001","value":"0.081","spread":"0.2603"}]}]},{"title":"CFB at Week 51 n=103,95","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"95"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.026","spread":"0.1682"},{"groupId":"OG001","value":"0.067","spread":"0.2840"}]}]},{"title":"CFB at Week 54 n=104,90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.043","spread":"0.1703"},{"groupId":"OG001","value":"0.054","spread":"0.3086"}]}]},{"title":"CFB at Week 57 n=109,86","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.037","spread":"0.2012"},{"groupId":"OG001","value":"0.049","spread":"0.2979"}]}]},{"title":"CFB at Week 60 n=94,84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.022","spread":"0.2119"},{"groupId":"OG001","value":"0.069","spread":"0.2819"}]}]},{"title":"CFB at Week 63 n=94,76","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"76"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.034","spread":"0.2056"},{"groupId":"OG001","value":"0.082","spread":"0.3043"}]}]},{"title":"CFB at Week 66 n=89,79","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.026","spread":"0.2011"},{"groupId":"OG001","value":"0.071","spread":"0.2996"}]}]},{"title":"CFB at Week 69 n=93,74","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.052","spread":"0.1805"},{"groupId":"OG001","value":"0.061","spread":"0.2964"}]}]},{"title":"CFB at Week 72 n=87,70","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.032","spread":"0.1890"},{"groupId":"OG001","value":"0.057","spread":"0.3176"}]}]},{"title":"CFB at Week 75 n=78,69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.021","spread":"0.1797"},{"groupId":"OG001","value":"0.080","spread":"0.2966"}]}]},{"title":"CFB at Week 78 n=77,64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.027","spread":"0.1979"},{"groupId":"OG001","value":"0.056","spread":"0.3064"}]}]},{"title":"CFB at Week 81 n=73,61","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.035","spread":"0.1844"},{"groupId":"OG001","value":"0.042","spread":"0.3529"}]}]},{"title":"CFB at Week 84 n=63,59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"59"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.056","spread":"0.1923"},{"groupId":"OG001","value":"0.064","spread":"0.3125"}]}]},{"title":"CFB at Week 87 n=44,43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.049","spread":"0.1894"},{"groupId":"OG001","value":"0.057","spread":"0.3474"}]}]},{"title":"CFB at Week 90 n=37,30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.050","spread":"0.1610"},{"groupId":"OG001","value":"0.039","spread":"0.3502"}]}]},{"title":"CFB at Week 93 n=24,24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.082","spread":"0.1861"},{"groupId":"OG001","value":"0.074","spread":"0.4112"}]}]},{"title":"CFB at Week 96 n=19,14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.071","spread":"0.1604"},{"groupId":"OG001","value":"0.018","spread":"0.3986"}]}]},{"title":"CFB at Week 99 n=15,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.116","spread":"0.1755"},{"groupId":"OG001","value":"0.099","spread":"0.4211"}]}]},{"title":"CFB at Week 102 n=8,4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.144","spread":"0.1730"},{"groupId":"OG001","value":"-0.002","spread":"0.4701"}]}]},{"title":"CFB at Week 105 n=5,2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.073","spread":"0.1476"},{"groupId":"OG001","value":"-0.232","spread":"0.2489"}]}]},{"title":"CFB at Week 108 n=1,0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.121","spread":"NA","comment":"Standard deviation was not calculable due the single data point for the mean value."}]}]},{"title":"CFB at Efficacy Follow-up 1 n=9,10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.085","spread":"0.2034"},{"groupId":"OG001","value":"-0.153","spread":"0.4494"}]}]},{"title":"CFB at Efficacy Follow-up 2 n=2,4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.031","spread":"0.6781"},{"groupId":"OG001","value":"-0.195","spread":"0.4873"}]}]},{"title":"CFB at Efficacy Follow-up 3 n=2,1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.406","spread":"0.4349"},{"groupId":"OG001","value":"0.163","spread":"NA","comment":"Standard deviation was not calculable due the single data point for the mean value."}]}]},{"title":"CFB at Efficacy Follow-up 4 n=0,1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.292","spread":"NA","comment":"Standard deviation was not calculable due the single data point for the mean value."}]}]},{"title":"CFB at CFB at Efficacy Follow-up 5 n=1,0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.144","spread":"NA","comment":"Standard deviation was not calculable due the single data point for the mean value."}]}]},{"title":"CFB at Post-disease Progression (7 days) n=32,24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.126","spread":"0.2115"},{"groupId":"OG001","value":"-0.048","spread":"0.2844"}]}]},{"title":"CFB at Post-disease Progression (28 days) n=30,30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.031","spread":"0.2191"},{"groupId":"OG001","value":"-0.010","spread":"0.2854"}]}]}]},{"type":"SECONDARY","title":"Part 2 (Double-blind, Randomized, Placebo-controlled): Change From Baseline in Score as Per the EuroQol 5 Dimension 5 Level (EQ-5D-5L) Questionnaire - Visual Analog Scale (VAS)","description":"The EQ-5D-5L is a standardized questionnaire used to assess health-related quality of life, and it includes a Visual Analog Scale (VAS). The VAS score is obtained by asking the individual to rate their current health status on a scale from 0 to 100, where 0 represents the worst possible health state and 100 represents the best possible health state.\n\nThe change from baseline in EQ-5D-5L VAS score was calculated. A positive change from baseline indicates improvement in the health status. CFB = change from baseline","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment. Data are reported for Part 2 only.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Assessed every 3 weeks from Week 3 through Week 108, at follow-up visits 1, 2, 3, 4, and 5 (follow-up visits occurred every 26 days from week 108), and at 7 and 28 days post-disease progression, all up to a maximum of 3.5 years","groups":[{"id":"OG000","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG001","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"323"}]}],"classes":[{"title":"CFB at Week 3 n=254,249","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"254"},{"groupId":"OG001","value":"249"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"16.51"},{"groupId":"OG001","value":"3.2","spread":"18.35"}]}]},{"title":"CFB at Week 6 n=236,230","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"236"},{"groupId":"OG001","value":"230"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"16.04"},{"groupId":"OG001","value":"2.6","spread":"18.18"}]}]},{"title":"CFB at Week 9 n=220,219","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"219"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"15.23"},{"groupId":"OG001","value":"2.5","spread":"17.22"}]}]},{"title":"CFB at Week 12 n=192,214","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"192"},{"groupId":"OG001","value":"214"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"18.28"},{"groupId":"OG001","value":"3.3","spread":"16.78"}]}]},{"title":"CFB at Week 15 n=194,196","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"196"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"17.41"},{"groupId":"OG001","value":"2.7","spread":"18.72"}]}]},{"title":"CFB at Week 18 n=187,198","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"198"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"16.76"},{"groupId":"OG001","value":"4.4","spread":"17.66"}]}]},{"title":"CFB at Week 21 n=173,176","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"176"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"16.92"},{"groupId":"OG001","value":"2.3","spread":"18.49"}]}]},{"title":"CFB at Week 24 n=161,164","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"161"},{"groupId":"OG001","value":"164"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"17.15"},{"groupId":"OG001","value":"2.3","spread":"19.40"}]}]},{"title":"CFB at Week 27 n=158,155","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"155"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"16.38"},{"groupId":"OG001","value":"2.8","spread":"17.65"}]}]},{"title":"CFB at Week 30 n=141,145","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"145"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"16.45"},{"groupId":"OG001","value":"2.5","spread":"19.08"}]}]},{"title":"CFB at Week 33 n=137,124","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"124"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"14.50"},{"groupId":"OG001","value":"4.1","spread":"17.00"}]}]},{"title":"CFB at Week 36 n=130,119","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"119"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"14.79"},{"groupId":"OG001","value":"4.8","spread":"16.73"}]}]},{"title":"CFB at Week 39 n=134,119","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"119"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"15.25"},{"groupId":"OG001","value":"4.6","spread":"16.68"}]}]},{"title":"CFB at Week 42 n=125,103","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"103"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"15.15"},{"groupId":"OG001","value":"4.7","spread":"17.17"}]}]},{"title":"CFB at Week 45 n=125,100","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"100"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"16.15"},{"groupId":"OG001","value":"5.0","spread":"14.75"}]}]},{"title":"CFB at Week 48 n=112,105","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"105"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"16.62"},{"groupId":"OG001","value":"3.9","spread":"17.29"}]}]},{"title":"CFB at Week 51 n=104,95","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"95"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"15.94"},{"groupId":"OG001","value":"2.8","spread":"17.07"}]}]},{"title":"CFB at Week 54 n=104,90","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"90"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"14.43"},{"groupId":"OG001","value":"4.2","spread":"17.50"}]}]},{"title":"CFB at Week 57 n=110,86","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"16.63"},{"groupId":"OG001","value":"2.1","spread":"19.12"}]}]},{"title":"CFB at Week 60 n=95,84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"16.49"},{"groupId":"OG001","value":"2.8","spread":"17.46"}]}]},{"title":"CFB at Week 63 n=95,76","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"76"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"17.35"},{"groupId":"OG001","value":"3.0","spread":"20.02"}]}]},{"title":"CFB at Week 66 n=90,79","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"15.49"},{"groupId":"OG001","value":"4.6","spread":"19.36"}]}]},{"title":"CFB at Week 69 n=94,74","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"15.48"},{"groupId":"OG001","value":"5.6","spread":"18.30"}]}]},{"title":"CFB at Week 72 n=88,70","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"15.30"},{"groupId":"OG001","value":"3.6","spread":"19.21"}]}]},{"title":"CFB at Week 75 n=79,69","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"15.96"},{"groupId":"OG001","value":"5.1","spread":"19.12"}]}]},{"title":"CFB at Week 78 n=78,64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"17.65"},{"groupId":"OG001","value":"5.1","spread":"19.34"}]}]},{"title":"CFB at Week 81 n=73,61","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"16.10"},{"groupId":"OG001","value":"3.1","spread":"19.38"}]}]},{"title":"CFB at Week 84 n=64,59","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"59"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"16.33"},{"groupId":"OG001","value":"2.0","spread":"19.05"}]}]},{"title":"CFB at Week 87 n=44,43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"17.07"},{"groupId":"OG001","value":"1.7","spread":"18.35"}]}]},{"title":"CFB at Week 90 n=37,30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"17.04"},{"groupId":"OG001","value":"2.6","spread":"18.13"}]}]},{"title":"CFB at Week 93 n=24,24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"16.06"},{"groupId":"OG001","value":"0.7","spread":"16.75"}]}]},{"title":"CFB at Week 96 n=19,14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"15.01"},{"groupId":"OG001","value":"4.8","spread":"16.28"}]}]},{"title":"CFB at Week 99 n=15,9","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"12.09"},{"groupId":"OG001","value":"5.9","spread":"19.51"}]}]},{"title":"CFB at Week 102 n=8,4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"14.98"},{"groupId":"OG001","value":"0.5","spread":"21.63"}]}]},{"title":"CFB at Week 105 n=5,2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"19.49"},{"groupId":"OG001","value":"-15.5","spread":"7.78"}]}]},{"title":"CFB at Week 108 n=1,0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"NA","comment":"Standard deviation was not calculable due the single data point for the mean value."}]}]},{"title":"CFB at Efficacy Follow-up 1 n=9,10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"17.67"},{"groupId":"OG001","value":"-9.8","spread":"27.85"}]}]},{"title":"CFB at Efficacy Follow-up 2 n=2,4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"9.19"},{"groupId":"OG001","value":"-5.3","spread":"17.23"}]}]},{"title":"CFB at Efficacy Follow-up 3 n=2,1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":"19.09"},{"groupId":"OG001","value":"5.0","spread":"NA","comment":"Standard deviation was not calculable due the single data point for the mean value."}]}]},{"title":"CFB at Efficacy Follow-up 4 n=0,1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"21.0","spread":"NA","comment":"Standard deviation was not calculable due the single data point for the mean value."}]}]},{"title":"CFB at CFB at Efficacy Follow-up 5 n=1,0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"NA","comment":"Standard deviation was not calculable due the single data point for the mean value."}]}]},{"title":"CFB at Post-disease Progression (7 days) n=32,24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10.4","spread":"18.36"},{"groupId":"OG001","value":"-4.6","spread":"21.40"}]}]},{"title":"CFB at Post-disease Progression (28 days) n=30,30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"19.14"},{"groupId":"OG001","value":"-1.4","spread":"22.92"}]}]}]},{"type":"POST_HOC","title":"All Collected Deaths","description":"On-treatment deaths due to any cause were collected from first dose of study medication to 30 days after the last dose of study treatment. Post-treatment survival follow-up deaths were collected from Day 31 after last dose of study medication to the data cut-off date.","populationDescription":"The full analysis set (FAS) comprised all participants to whom study treatment was assigned and who received at least one dose of the study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"On-treatment deaths: Up to approximately 29 months in Part 1 or approximately 25 months in Part 2. Post-treatment survival follow-up deaths: Up to an additional 130 days.","groups":[{"id":"OG000","title":"Part 1: Cohort A","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and pemetrexed."},{"id":"OG001","title":"Part 1: Cohort B","description":"Safety run-in, canakinumab in combination with pembrolizumab, cisplatin, and pemetrexed."},{"id":"OG002","title":"Part 1: Cohort C","description":"Safety run-in, canakinumab in combination with pembrolizumab, carboplatin, and paclitaxel."},{"id":"OG003","title":"Part 2: Canakinumab+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy."},{"id":"OG004","title":"Part 2: Placebo+Pembro+CTx","description":"Double-blind, randomized, placebo-controlled, canakinumab-matching placebo in combination with pembrolizumab and platinum-based doublet chemotherapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"320"},{"groupId":"OG004","value":"323"}]}],"classes":[{"title":"Pre-treatment deaths","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"320"},{"groupId":"OG004","value":"323"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"On-treatment deaths","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"320"},{"groupId":"OG004","value":"322"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"97"},{"groupId":"OG004","value":"102"}]}]},{"title":"Post-treatment survival follow-up deaths","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"223"},{"groupId":"OG004","value":"220"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"57"}]}]},{"title":"All deaths","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"320"},{"groupId":"OG004","value":"323"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"147"},{"groupId":"OG004","value":"159"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events (AEs) were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of approximately 32 months.","description":"Any sign or symptom that occurred during the conduct of the trial and safety follow-up. Deaths in the post-treatment survival follow-up were not considered adverse events. The total number at risk in the post-treatment survival included patients that entered the post-treatment survival follow-up period. All-cause Mortality was assessed on the Full analysis set (FAS). SAEs and AEs were assessed on the Safety Set (participants who received at least one dose of the study treatment).","eventGroups":[{"id":"EG000","title":"Part 1: Cohort A (On-treatment)","description":"AEs during the on-treatment period (up to 30 days post-treatment)","deathsNumAffected":4,"deathsNumAtRisk":10,"seriousNumAffected":4,"seriousNumAtRisk":10,"otherNumAffected":10,"otherNumAtRisk":10},{"id":"EG001","title":"Part 1: Cohort B (On-treatment)","description":"AEs during the on-treatment period (up to 30 days post-treatment)","deathsNumAffected":1,"deathsNumAtRisk":11,"seriousNumAffected":3,"seriousNumAtRisk":11,"otherNumAffected":11,"otherNumAtRisk":11},{"id":"EG002","title":"Part 1: Cohort C (On-treatment)","description":"AEs during the on-treatment period (up to 30 days post-treatment)","deathsNumAffected":4,"deathsNumAtRisk":9,"seriousNumAffected":4,"seriousNumAtRisk":9,"otherNumAffected":9,"otherNumAtRisk":9},{"id":"EG003","title":"Part 2: Canakinumab+Pembro+CTx (On-treatment)","description":"AEs during the on-treatment period (up to 30 days post-treatment)","deathsNumAffected":97,"deathsNumAtRisk":320,"seriousNumAffected":174,"seriousNumAtRisk":320,"otherNumAffected":309,"otherNumAtRisk":320},{"id":"EG004","title":"Part 2: Placebo+Pembro+CTx (On-treatment)","description":"AEs during the on-treatment period (up to 30 days post-treatment)","deathsNumAffected":102,"deathsNumAtRisk":323,"seriousNumAffected":167,"seriousNumAtRisk":322,"otherNumAffected":310,"otherNumAtRisk":322},{"id":"EG005","title":"Part 1: Cohort A (Post-treatment Survival Follow-up)","description":"Deaths collected in the post-treatment survival follow-up period (starting from Day 31 post-treatment). No AEs were collected during this period.","deathsNumAffected":2,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0},{"id":"EG006","title":"Part 1: Cohort B (Post-treatment Survival Follow-up)","description":"Deaths collected in the post-treatment survival follow-up period (starting from Day 31 post-treatment). No AEs were collected during this period.","deathsNumAffected":5,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0},{"id":"EG007","title":"Part 1: Cohort C (Post-treatment Survival Follow-up)","description":"Deaths collected in the post-treatment survival follow-up period (starting from Day 31 post-treatment). No AEs were collected during this period.","deathsNumAffected":3,"deathsNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0},{"id":"EG008","title":"Part 2: Canakinumab+Pembro+CTx (Post-treatment Survival Follow-up)","description":"Deaths collected in the post-treatment survival follow-up period (starting from Day 31 post-treatment). No AEs were collected during this period.","deathsNumAffected":50,"deathsNumAtRisk":223,"seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0},{"id":"EG009","title":"Part 2: Placebo+Pembro+CTx (Post-treatment Survival Follow-up)","description":"Deaths collected in the post-treatment survival follow-up period (starting from Day 31 post-treatment). No AEs were collected during this period.","deathsNumAffected":57,"deathsNumAtRisk":220,"seriousNumAffected":0,"seriousNumAtRisk":0,"otherNumAffected":0,"otherNumAtRisk":0}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":10,"numAtRisk":320},{"groupId":"EG004","numAffected":11,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Bicytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Coagulopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Disseminated intravascular coagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":10,"numAtRisk":320},{"groupId":"EG004","numAffected":8,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Granulocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Immune-mediated cytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":7,"numAtRisk":320},{"groupId":"EG004","numAffected":8,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Atrioventricular block complete","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cardiogenic shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cardiovascular disorder","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Coronary artery stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Ventricular arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Adrenal disorder","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Glucocorticoid deficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypercalcaemia of malignancy","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypophysitis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Diplopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Autoimmune colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":7,"numAtRisk":320},{"groupId":"EG004","numAffected":10,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Diarrhoea haemorrhagic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Intestinal ischaemia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Large intestine perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Mesenteric artery thrombosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Oesophageal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":5,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":4,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Condition aggravated","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Feeling abnormal","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Generalised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Implant site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Localised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":12,"numAtRisk":320},{"groupId":"EG004","numAffected":8,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cholestasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hepatic cytolysis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hepatitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Abdominal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Abscess limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Asymptomatic COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":4,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Atypical pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Bacterial sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Biliary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":5,"numAtRisk":320},{"groupId":"EG004","numAffected":6,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dengue fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Escherichia bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Gastroenteritis clostridial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Gastrointestinal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Gastrointestinal protozoal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Herpes virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Infective exacerbation of chronic obstructive airways disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Klebsiella sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Meningitis aseptic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Nosocomial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Peritonitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":32,"numAtRisk":320},{"groupId":"EG004","numAffected":25,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pneumonia cytomegaloviral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pneumonia pseudomonal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":4,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":6,"numAtRisk":320},{"groupId":"EG004","numAffected":10,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":5,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Tracheobronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Urinary tract infection bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Vascular device infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Periprosthetic fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Post procedural complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Transfusion-related circulatory overload","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":4,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cortisol decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Eastern Cooperative Oncology Group performance status worsened","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":6,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":6,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Troponin I increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hyperglycaemic hyperosmolar nonketotic syndrome","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":4,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypophagia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Type 1 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":5,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Necrotising myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Bladder neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Blast crisis in myelogenous leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Malignant melanoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Squamous cell carcinoma of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Transitional cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Altered state of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cerebellar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Diabetic neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Diplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hemianopia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Schizophrenia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":5,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Chronic kidney disease","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Tubulointerstitial nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Ureteric obstruction","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Postmenopausal haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Bronchial fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":16,"numAtRisk":320},{"groupId":"EG004","numAffected":13,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dyspnoea paroxysmal nocturnal","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":6,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Laryngeal obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Lung disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":9,"numAtRisk":320},{"groupId":"EG004","numAffected":8,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":9,"numAtRisk":320},{"groupId":"EG004","numAffected":6,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":8,"numAtRisk":320},{"groupId":"EG004","numAffected":6,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":4,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Immune-mediated dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Panniculitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Arteriosclerosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Extremity necrosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Jugular vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":10},{"groupId":"EG001","numAffected":3,"numAtRisk":11},{"groupId":"EG002","numAffected":3,"numAtRisk":9},{"groupId":"EG003","numAffected":153,"numAtRisk":320},{"groupId":"EG004","numAffected":148,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":26,"numAtRisk":320},{"groupId":"EG004","numAffected":15,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":124,"numAtRisk":320},{"groupId":"EG004","numAffected":78,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":58,"numAtRisk":320},{"groupId":"EG004","numAffected":42,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":6,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":2,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":5,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":2,"numAtRisk":9},{"groupId":"EG003","numAffected":19,"numAtRisk":320},{"groupId":"EG004","numAffected":14,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":31,"numAtRisk":320},{"groupId":"EG004","numAffected":28,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Conjunctivitis allergic","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":7,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Endocrine ophthalmopathy","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":3,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":9,"numAtRisk":320},{"groupId":"EG004","numAffected":7,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":4,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Visual impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Xerophthalmia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":5,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":3,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":14,"numAtRisk":320},{"groupId":"EG004","numAffected":19,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":10,"numAtRisk":320},{"groupId":"EG004","numAffected":5,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Anal incontinence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Anal inflammation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":10},{"groupId":"EG001","numAffected":3,"numAtRisk":11},{"groupId":"EG002","numAffected":2,"numAtRisk":9},{"groupId":"EG003","numAffected":84,"numAtRisk":320},{"groupId":"EG004","numAffected":81,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":2,"numAtRisk":9},{"groupId":"EG003","numAffected":61,"numAtRisk":320},{"groupId":"EG004","numAffected":66,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":10,"numAtRisk":320},{"groupId":"EG004","numAffected":5,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":9,"numAtRisk":320},{"groupId":"EG004","numAffected":9,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":7,"numAtRisk":320},{"groupId":"EG004","numAffected":9,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Glossodynia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":10},{"groupId":"EG001","numAffected":5,"numAtRisk":11},{"groupId":"EG002","numAffected":5,"numAtRisk":9},{"groupId":"EG003","numAffected":115,"numAtRisk":320},{"groupId":"EG004","numAffected":124,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Odynophagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Oesophageal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":11,"numAtRisk":320},{"groupId":"EG004","numAffected":17,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":10},{"groupId":"EG001","numAffected":5,"numAtRisk":11},{"groupId":"EG002","numAffected":2,"numAtRisk":9},{"groupId":"EG003","numAffected":54,"numAtRisk":320},{"groupId":"EG004","numAffected":51,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":3,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":93,"numAtRisk":320},{"groupId":"EG004","numAffected":87,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":5,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":18,"numAtRisk":320},{"groupId":"EG004","numAffected":18,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Effusion","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10},{"groupId":"EG001","numAffected":5,"numAtRisk":11},{"groupId":"EG002","numAffected":3,"numAtRisk":9},{"groupId":"EG003","numAffected":59,"numAtRisk":320},{"groupId":"EG004","numAffected":68,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Generalised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":7,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":8,"numAtRisk":320},{"groupId":"EG004","numAffected":6,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":17,"numAtRisk":320},{"groupId":"EG004","numAffected":17,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":5,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":35,"numAtRisk":320},{"groupId":"EG004","numAffected":42,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":9,"numAtRisk":320},{"groupId":"EG004","numAffected":8,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":44,"numAtRisk":320},{"groupId":"EG004","numAffected":65,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Swelling face","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Allergic reaction to excipient","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Borrelia infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Candida infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":10,"numAtRisk":320},{"groupId":"EG004","numAffected":13,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Eye infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":2,"numAtRisk":9},{"groupId":"EG003","numAffected":5,"numAtRisk":320},{"groupId":"EG004","numAffected":7,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":8,"numAtRisk":320},{"groupId":"EG004","numAffected":6,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":26,"numAtRisk":320},{"groupId":"EG004","numAffected":16,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10},{"groupId":"EG001","numAffected":3,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":18,"numAtRisk":320},{"groupId":"EG004","numAffected":15,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":19,"numAtRisk":320},{"groupId":"EG004","numAffected":20,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Vaginal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Viral rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":8,"numAtRisk":320},{"groupId":"EG004","numAffected":4,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":76,"numAtRisk":320},{"groupId":"EG004","numAffected":50,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":32,"numAtRisk":320},{"groupId":"EG004","numAffected":39,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":62,"numAtRisk":320},{"groupId":"EG004","numAffected":47,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":25,"numAtRisk":320},{"groupId":"EG004","numAffected":22,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Blood cholesterol increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":6,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":28,"numAtRisk":320},{"groupId":"EG004","numAffected":42,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":49,"numAtRisk":320},{"groupId":"EG004","numAffected":37,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":19,"numAtRisk":320},{"groupId":"EG004","numAffected":31,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":27,"numAtRisk":320},{"groupId":"EG004","numAffected":14,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":10},{"groupId":"EG001","numAffected":3,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":79,"numAtRisk":320},{"groupId":"EG004","numAffected":58,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":50,"numAtRisk":320},{"groupId":"EG004","numAffected":32,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"SARS-CoV-2 test negative","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":36,"numAtRisk":320},{"groupId":"EG004","numAffected":42,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":31,"numAtRisk":320},{"groupId":"EG004","numAffected":30,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":63,"numAtRisk":320},{"groupId":"EG004","numAffected":43,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":10},{"groupId":"EG001","numAffected":5,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":91,"numAtRisk":320},{"groupId":"EG004","numAffected":79,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Diabetes mellitus inadequate control","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":7,"numAtRisk":320},{"groupId":"EG004","numAffected":6,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":2,"numAtRisk":9},{"groupId":"EG003","numAffected":24,"numAtRisk":320},{"groupId":"EG004","numAffected":26,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":20,"numAtRisk":320},{"groupId":"EG004","numAffected":16,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":33,"numAtRisk":320},{"groupId":"EG004","numAffected":32,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":25,"numAtRisk":320},{"groupId":"EG004","numAffected":34,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":24,"numAtRisk":320},{"groupId":"EG004","numAffected":18,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Polydipsia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":4,"numAtRisk":11},{"groupId":"EG002","numAffected":2,"numAtRisk":9},{"groupId":"EG003","numAffected":49,"numAtRisk":320},{"groupId":"EG004","numAffected":56,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":26,"numAtRisk":320},{"groupId":"EG004","numAffected":32,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":8,"numAtRisk":320},{"groupId":"EG004","numAffected":7,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":5,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":2,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":10,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":13,"numAtRisk":320},{"groupId":"EG004","numAffected":11,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":3,"numAtRisk":11},{"groupId":"EG002","numAffected":3,"numAtRisk":9},{"groupId":"EG003","numAffected":25,"numAtRisk":320},{"groupId":"EG004","numAffected":28,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":6,"numAtRisk":320},{"groupId":"EG004","numAffected":9,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":3,"numAtRisk":9},{"groupId":"EG003","numAffected":22,"numAtRisk":320},{"groupId":"EG004","numAffected":22,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Sjogren's syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Metastases to skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":23,"numAtRisk":320},{"groupId":"EG004","numAffected":21,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":15,"numAtRisk":320},{"groupId":"EG004","numAffected":16,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":21,"numAtRisk":320},{"groupId":"EG004","numAffected":33,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":9,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":4,"numAtRisk":9},{"groupId":"EG003","numAffected":22,"numAtRisk":320},{"groupId":"EG004","numAffected":18,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":3,"numAtRisk":9},{"groupId":"EG003","numAffected":24,"numAtRisk":320},{"groupId":"EG004","numAffected":20,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":6,"numAtRisk":320},{"groupId":"EG004","numAffected":6,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":5,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Taste disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":11,"numAtRisk":320},{"groupId":"EG004","numAffected":11,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":2,"numAtRisk":9},{"groupId":"EG003","numAffected":29,"numAtRisk":320},{"groupId":"EG004","numAffected":31,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":5,"numAtRisk":320},{"groupId":"EG004","numAffected":5,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":5,"numAtRisk":320},{"groupId":"EG004","numAffected":7,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Nocturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Polyuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":3,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Heavy menstrual bleeding","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":10},{"groupId":"EG001","numAffected":3,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":54,"numAtRisk":320},{"groupId":"EG004","numAffected":51,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":10},{"groupId":"EG001","numAffected":4,"numAtRisk":11},{"groupId":"EG002","numAffected":3,"numAtRisk":9},{"groupId":"EG003","numAffected":59,"numAtRisk":320},{"groupId":"EG004","numAffected":61,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":9,"numAtRisk":320},{"groupId":"EG004","numAffected":11,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":16,"numAtRisk":320},{"groupId":"EG004","numAffected":22,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":4,"numAtRisk":320},{"groupId":"EG004","numAffected":8,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":10,"numAtRisk":320},{"groupId":"EG004","numAffected":5,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":16,"numAtRisk":320},{"groupId":"EG004","numAffected":21,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":8,"numAtRisk":320},{"groupId":"EG004","numAffected":5,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Tonsillar ulcer","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":2,"numAtRisk":9},{"groupId":"EG003","numAffected":29,"numAtRisk":320},{"groupId":"EG004","numAffected":31,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":15,"numAtRisk":320},{"groupId":"EG004","numAffected":14,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":7,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":5,"numAtRisk":320},{"groupId":"EG004","numAffected":9,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Ingrowing nail","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":48,"numAtRisk":320},{"groupId":"EG004","numAffected":43,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":5,"numAtRisk":11},{"groupId":"EG002","numAffected":2,"numAtRisk":9},{"groupId":"EG003","numAffected":51,"numAtRisk":320},{"groupId":"EG004","numAffected":61,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":2,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":10,"numAtRisk":320},{"groupId":"EG004","numAffected":10,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":1,"numAtRisk":320},{"groupId":"EG004","numAffected":5,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":2,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":1,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":3,"numAtRisk":320},{"groupId":"EG004","numAffected":4,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":11},{"groupId":"EG002","numAffected":1,"numAtRisk":9},{"groupId":"EG003","numAffected":24,"numAtRisk":320},{"groupId":"EG004","numAffected":22,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":13,"numAtRisk":320},{"groupId":"EG004","numAffected":6,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]},{"term":"Subclavian vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":11},{"groupId":"EG002","numAffected":0,"numAtRisk":9},{"groupId":"EG003","numAffected":0,"numAtRisk":320},{"groupId":"EG004","numAffected":0,"numAtRisk":322},{"groupId":"EG005","numAtRisk":0},{"groupId":"EG006","numAtRisk":0},{"groupId":"EG007","numAtRisk":0},{"groupId":"EG008","numAtRisk":0},{"groupId":"EG009","numAtRisk":0}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."},"pointOfContact":{"title":"Study Director","organization":"Novartis Pharmaceuticals","email":"novartis.email@novartis.com","phone":"+ 1 862 778 8300"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-08-25","uploadDate":"2025-06-27T12:18","filename":"Prot_002.pdf","size":2532263},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-07-03","uploadDate":"2024-07-05T13:23","filename":"SAP_001.pdf","size":3063145}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["South Africa"],"submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-07-31","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D009362","term":"Neoplasm Metastasis"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D009385","term":"Neoplastic Processes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"C541220","term":"canakinumab"},{"id":"C582435","term":"pembrolizumab"},{"id":"D016190","term":"Carboplatin"},{"id":"D002945","term":"Cisplatin"},{"id":"D017239","term":"Paclitaxel"},{"id":"C520255","term":"130-nm albumin-bound paclitaxel"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}